Team
Maha Ayyoub
T2i :
Anti-tumour immunity and immunotherapy
The specificities
of our research axis
Tumour antigen-specific T cells
T cell depletion
Immune checkpoint inhibitor immunotherapy
Anti-cancer vaccines
Clinical trials
Pre-clinical orthotopic models
Genomics
Trancriptomics
Research
projects
Immune complexity of epithelial cancers
Pr Alejandra Martinez et Dr Anna Salvioni
Impact of tumour immune microenvironments on the response to immunotherapies
Christel Devaud
Targeting autophagy in cancer immunotherapy
Sylvie Giuriato
Setting up clinical trials and immune monitoring of patients treated with immunotherapy.
Clara-Maria Scarlata
Role of tumour ag-specific T cells in the clinical response to immunotherapy
Pr Maha Ayyoub
THE TEAM’S
FOCUS
Discover
Understand
Participate
Live Feed
;
Thrilled to announce that @Institut_cancer has awarded a 5 yr label to the COALA (Cure Oncogene Addicted Lung Adenocarcinoma) network that gathers 15 research teams in France. Looking forward to starting the program and improving patients outcome. @CHUdeToulouse @crctoncopole
Scientific production
PUBLICATIONS 2026
7813506
FGRJFWV3
2026
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%228PFU7MY3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zach%20et%20al.%22%2C%22parsedDate%22%3A%222026-02-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZach%2C%20Diana%2C%20Denis%20Querleu%2C%20Mahmood%20Ul%20Hassan%2C%20Matteo%20Loverro%2C%20Giulio%20Ricotta%2C%20Mihai%20Emil%20C%26%23xE3%3Bp%26%23xEE%3Blna%2C%20Santiago%20Domingo%2C%20et%20al.%20%26%23x201C%3BPelvic%20Exenteration%20for%20Vulvar%20Cancer%3A%20Contemporary%20Outcomes%20from%20a%20Multinational%20Cohort%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Surgical%20Oncology%3A%20The%20Journal%20of%20the%20European%20Society%20of%20Surgical%20Oncology%20and%20the%20British%20Association%20of%20Surgical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2052%2C%20no.%204%20%28February%2019%2C%202026%29%3A%20111468.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2026.111468%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2026.111468%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pelvic%20exenteration%20for%20vulvar%20cancer%3A%20contemporary%20outcomes%20from%20a%20multinational%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Zach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmood%22%2C%22lastName%22%3A%22Ul%20Hassan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matteo%22%2C%22lastName%22%3A%22Loverro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%22%2C%22lastName%22%3A%22Ricotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihai%20Emil%22%2C%22lastName%22%3A%22C%5Cu00e3p%5Cu00eelna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%22%2C%22lastName%22%3A%22Domingo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cibula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoltan%22%2C%22lastName%22%3A%22Nov%5Cu00e1k%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Miranda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrique%22%2C%22lastName%22%3A%22Chacon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignacio%22%2C%22lastName%22%3A%22Zapardiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentyn%22%2C%22lastName%22%3A%22Svintsitskyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Matylevich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabrielle%20H.%22%2C%22lastName%22%3A%22van%20Ramshorst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cagatay%22%2C%22lastName%22%3A%22Taskiran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fuat%22%2C%22lastName%22%3A%22Demirk%5Cu0131ran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Vizzielli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Fanfani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgia%22%2C%22lastName%22%3A%22Garganese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Fagotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gauroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Cucinella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mustafa%20Zelal%22%2C%22lastName%22%3A%22Muallem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicol%5Cu00f2%22%2C%22lastName%22%3A%22Bizzarri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahar%22%2C%22lastName%22%3A%22Salehi%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Women%20with%20vulvar%20cancer%20are%20considerably%20older%20than%20those%20with%20other%20gynaecological%20malignancies%2C%20raising%20concerns%20about%20the%20tolerability%20of%20radical%20surgery.%20Yet%2C%20for%20locally%20advanced%20or%20recurrent%20disease%2C%20pelvic%20exenteration%20may%20be%20the%20only%20curative%20option.%20Robust%20evidence%20to%20guide%20decision-making%20in%20this%20population%20is%20lacking.%5CnMATERIAL%20AND%20METHODS%3A%20This%20multicentre%20observational%20cohort%20study%20used%20data%20from%20the%20COREPEX%20registry%20including%20women%20who%20underwent%20anterior%20or%20total%20pelvic%20exenteration%20between%202005%20and%202023%20across%2020%20European%20tertiary%20referral%20centres.%20The%20primary%20outcome%20was%20overall%20survival%20%28OS%29%3B%20secondary%20outcomes%20were%20progression-free%20survival%20%28PFS%29%20and%20major%20postoperative%20complications.%20Associations%20were%20assessed%20using%20multivariable%20Cox%20and%20binomial%20regression%20models%20adjusted%20for%20relevant%20covariates.%5CnRESULTS%3A%20Among%20861%20women%2C%2079%20%289.2%25%29%20had%20vulvar%20cancer.%20Median%20follow-up%20was%2049%20months%20for%20OS%20and%2040%20months%20for%20PFS.%20Women%20with%20vulvar%20cancer%20were%20older%20and%20more%20often%20overweight.%20Five-year%20OS%20was%2032%25%20%2895%25%20CI%2C%2019-46%29%20in%20vulvar%20cancer%20versus%2029%25%20%2895%25%20CI%2C%2025-34%29%20in%20other%20cancers%2C%20adjusted%20HR%201.05%20%2895%25%20CI%2C%200.75-1.46%29.%20Five-year%20PFS%20was%2034%25%20versus%2029%25%2C%20adjusted%20HR%200.96%20%2895%25%20CI%2C%200.69-1.34%29.%20Major%20complications%20occurred%20in%2033%25%20vs%2029%25%2C%20adjusted%20RR%201.12%20%2895%25%20CI%2C%200.77-1.58%29.%20Lymph%20node%20metastases%2C%20positive%20margins%2C%20and%20recurrent%20or%20persistent%20disease%20independently%20predicted%20poorer%20survival.%5CnCONCLUSION%3A%20Despite%20their%20older%20age%2C%20women%20with%20vulvar%20cancer%20had%20survival%20and%20morbidity%20comparable%20to%20those%20with%20other%20gynaecological%20malignancies.%20These%20findings%20support%20pelvic%20exenteration%20as%20a%20curative%20option%20for%20selected%20women%20with%20vulvar%20cancer%20when%20complete%20resection%20is%20feasible.%22%2C%22date%22%3A%222026-02-19%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejso.2026.111468%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221532-2157%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-02-23T08%3A40%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22CSIG2MYZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bizzarri%20et%20al.%22%2C%22parsedDate%22%3A%222026-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBizzarri%2C%20Nicol%26%23xF2%3B%2C%20Denis%20Querleu%2C%20Giulio%20Ricotta%2C%20Diana%20Giannarelli%2C%20Mihai%20Emil%20C%26%23xE3%3Bp%26%23xEE%3Blna%2C%20Santiago%20Domingo%2C%20Vito%20Chiantera%2C%20et%20al.%20%26%23x201C%3BComplications%20and%20Recurrence%20after%20Pelvic%20Exenteration%20for%20Gynecologic%20Malignancies%3A%20Analysis%20of%20Surgical%20Complications%20from%20the%20COREPEX%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2036%2C%20no.%202%20%28February%202026%29%3A%20102820.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijgc.2025.102820%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijgc.2025.102820%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Complications%20and%20recurrence%20after%20pelvic%20exenteration%20for%20gynecologic%20malignancies%3A%20Analysis%20of%20surgical%20complications%20from%20the%20COREPEX%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicol%5Cu00f2%22%2C%22lastName%22%3A%22Bizzarri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%22%2C%22lastName%22%3A%22Ricotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Giannarelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihai%20Emil%22%2C%22lastName%22%3A%22C%5Cu00e3p%5Cu00eelna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%22%2C%22lastName%22%3A%22Domingo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vito%22%2C%22lastName%22%3A%22Chiantera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00fcseyin%22%2C%22lastName%22%3A%22Ak%5Cu0131ll%5Cu0131%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cibula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoltan%22%2C%22lastName%22%3A%22Nov%5Cu00e1k%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Zach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Miranda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Porfyrios%22%2C%22lastName%22%3A%22Korompelis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Chiva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignacio%22%2C%22lastName%22%3A%22Zapardiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bj%5Cu00f6rn%22%2C%22lastName%22%3A%22Lampe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentyn%22%2C%22lastName%22%3A%22Svintsitskyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Matylevich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabrielle%20H.%22%2C%22lastName%22%3A%22van%20Ramshorst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cagatay%22%2C%22lastName%22%3A%22Taskiran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fuat%22%2C%22lastName%22%3A%22Demirk%5Cu0131ran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tibor%22%2C%22lastName%22%3A%22Lengyel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Vizzielli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matteo%22%2C%22lastName%22%3A%22Loverro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gauroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Ladanyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leo%20Szilard%22%2C%22lastName%22%3A%22Kiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Lago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manel%22%2C%22lastName%22%3A%22Montesinos-Albert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariano%20Catello%22%2C%22lastName%22%3A%22Di%20Donna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Cucinella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Ayhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiri%22%2C%22lastName%22%3A%22Slama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vikt%5Cu00f3ria%22%2C%22lastName%22%3A%22Rosta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahar%22%2C%22lastName%22%3A%22Salehi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mustafa%20Zelal%22%2C%22lastName%22%3A%22Muallem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Kucukmetin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Scambia%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20This%20study%20aimed%20to%20assess%20intra-operative%2C%20short-term%2C%20and%20long-term%20morbidity%20and%20develop%20a%20score%20predicting%20post-operative%20complications%20after%20pelvic%20exenteration%20for%20gynecologic%20cancer.%5CnMETHODS%3A%20This%20was%20a%20retrospective%2C%20multi-center%2C%20international%20study%20conducted%20in%20tertiary%20referral%20centers%20for%20gynecologic%20oncology.%20The%20inclusion%20criteria%20included%20cervical%2C%20vaginal%2C%20vulvar%2C%20or%20endometrial%20cancer%3B%20anterior%5C%2Ftotal%20pelvic%20exenteration%20performed%20between%20January%202005%20and%20March%202023%3B%20curative%5C%2Fpalliative%20intent%3B%20with%20or%20without%20laterally%20extended%20endopelvic%5C%2Fpelvic%20resection.%20Logistic%20regression%20adjusted%20for%20co-variables%20and%20a%20score%20predictive%20of%20severe%20post-operative%20complications%20based%20on%20the%20multi-variable%20analysis%20were%20developed.%5CnRESULTS%3A%20A%20total%20of%20862%20patients%20were%20included.%20Seven%20patients%20%280.8%25%29%20had%20severe%20intra-operative%20complications%2C%20and%20no%20patient%20experienced%20intra-operative%20death.%20A%20total%20of%20225%20patients%20%2826.1%25%29%20had%20severe%20early%20post-operative%20complications%20and%2027%20%283.1%25%29%20died%20within%2030%20days.%20The%20most%20frequent%20severe%20early%20post-operative%20complications%20were%20pelvic%20abscess%5C%2Fcollection%20%2823.4%25%29%20and%20urostomy%20leak%5C%2Ffistula%20%2813.4%25%29.%20A%20total%20of%2087%20patients%20%2810.1%25%29%20had%20severe%20late%20post-operative%20complications%2C%20and%2016%20patients%20%281.8%25%29%20died%20between%2031%20and%20180%20days.%20The%20most%20frequent%20severe%20late%20post-operative%20complications%20were%20pelvic%20abscess%5C%2Fcollection%20%2821.6%25%29%20and%20benign%20ureteric%20stricture%20%2813.5%25%29.%20Risk%20factors%20independently%20associated%20with%20severe%20early%20and%20late%20post-operative%20complications%20were%20no%20previous%20recurrences%2C%20American%20Society%20of%20Anesthesiologists%20score%20%26gt%3B1%2C%20total%20pelvic%20exenteration%2C%20infra-levator%20pelvic%20exenteration%2C%20laterally%20extended%20endopelvic%5C%2Fpelvic%20resection%3B%20and%20infra-levator%20pelvic%20exenteration%20and%20laterally%20extended%20endopelvic%5C%2Fpelvic%20resection%2C%20respectively.%20The%20COREPEX%20predictive%20score%20identified%204%20groups%20with%20significantly%20different%20risk%20of%20severe%20post-operative%20complications%20%28p%20%26lt%3B%20.001%29.%5CnCONCLUSIONS%3A%20Patients%20undergoing%20anterior%20or%20total%20pelvic%20exenteration%20have%20a%20low%20risk%20of%20intra-operative%20but%20a%20remarkable%20risk%20of%20major%20post-operative%20complications.%20No%20intra-operative%20death%20was%20recorded%2C%20and%20post-operative%20mortality%20was%20low.%20The%20COREPEX%20score%20predicting%20the%20risk%20of%20post-operative%20complications%20can%20be%20used%20to%20counsel%20patients%20and%20for%20future%20studies.%22%2C%22date%22%3A%222026-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijgc.2025.102820%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-02-09T17%3A19%3A11Z%22%7D%7D%5D%7D
Zach, Diana, Denis Querleu, Mahmood Ul Hassan, Matteo Loverro, Giulio Ricotta, Mihai Emil Cãpîlna, Santiago Domingo, et al. “Pelvic Exenteration for Vulvar Cancer: Contemporary Outcomes from a Multinational Cohort Study.” European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 52, no. 4 (February 19, 2026): 111468. https://doi.org/10.1016/j.ejso.2026.111468.
Bizzarri, Nicolò, Denis Querleu, Giulio Ricotta, Diana Giannarelli, Mihai Emil Cãpîlna, Santiago Domingo, Vito Chiantera, et al. “Complications and Recurrence after Pelvic Exenteration for Gynecologic Malignancies: Analysis of Surgical Complications from the COREPEX Study.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 36, no. 2 (February 2026): 102820. https://doi.org/10.1016/j.ijgc.2025.102820.
PUBLICATIONS 2025
7813506
FGRJFWV3
2025
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Z5G9A3QN%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Monnereau%20et%20al.%22%2C%22parsedDate%22%3A%222025-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMonnereau%2C%20Matthias%2C%20Jean-Pierre%20Delord%2C%20Stefan%20Michiels%2C%20Christophe%20Le%20Tourneau%2C%20Sebastien%20Marque%2C%20Louise%20Baschet%2C%20and%20Thomas%20Filleron.%20%26%23x201C%3BAcceptance%20of%20External%20Control%20Arms%20by%20HTA%20Agencies%3A%20A%20Review%20of%20Oncology%20Submissions%20in%20France%2C%20England%2C%20Germany%20and%20Norway%20from%202021%20to%202023.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBritish%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20133%2C%20no.%2010%20%28November%202025%29%3A%201501%26%23x2013%3B7.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-025-03155-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-025-03155-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acceptance%20of%20external%20control%20arms%20by%20HTA%20agencies%3A%20a%20review%20of%20oncology%20submissions%20in%20France%2C%20England%2C%20Germany%20and%20Norway%20from%202021%20to%202023%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Monnereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Michiels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Le%20Tourneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Marque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Baschet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20External%20control%20arms%20%28ECAs%29%20are%20sometimes%20considered%20as%20an%20alternative%20to%20phase%20III%20trials%2C%20enabling%20comparisons%20without%20head-to-head%20trials.%20Deploying%20ECAs%20is%20complex%2C%20partially%20due%20to%20varying%20regulatory%20guidelines.%20We%20aimed%20to%20assess%20their%20acceptance%20in%20oncology%20by%20Health%20Technology%20Assessment%20%28HTA%29%20bodies%20across%20France%2C%20England%2C%20Germany%2C%20and%20Norway%20from%202021%20to%202023.%5CnMETHODS%3A%20We%20conducted%20a%20review%20of%20HTA%20evaluation%20reports%20for%20oncology%20treatments%20using%20ECAs.%20Reports%20were%20extracted%20from%20national%20HTA%20body%20websites%20and%20systematically%20reviewed.%20Data%20extraction%20included%20drug%20characteristics%2C%20ECA%20methodology%2C%20acceptance%20status%2C%20and%20reported%20issues.%20ECAs%20were%20categorized%20by%20type%20of%20data%3A%20Individual%20Patient%20Data%20%28IPD%29%2C%20Aggregated%20Data%20%28AgD%29%2C%20or%20naive%20comparisons.%5CnRESULTS%3A%20We%20analysed%20175%20ECAs%20from%20123%20reviews%2C%20none%20were%20accepted%20without%20restrictions%2C%20and%20only%2017%25%20were%20not%20rejected.%20Acceptance%20rates%20varied%20significantly%20between%20countries%2C%20with%20England%20showing%20the%20highest%20non-rejection%20rate%20%28accepted%20with%20restrictions%29%20%2841%25%29%2C%20followed%20by%20France%20%2814%25%29%20while%20Germany%20and%20Norway%20rejected%20all%20ECAs.%20The%20main%20methodological%20issues%20identified%20were%20lack%20of%5C%2Funclear%20data%20%2854%25%29%2C%20heterogeneity%20between%20studies%20or%20risk%20of%20bias%20%2851%25%29%2C%20study%20design%20concerns%20%2829%25%29%2C%20and%20statistical%20methodology%20limitations%20%2826%25%29.%20These%20challenges%20were%20consistent%20across%20different%20types%20of%20ECAs%2C%20though%20their%20relative%20importance%20varied%20by%20country.%5CnCONCLUSIONS%3A%20Despite%20the%20increasing%20use%20of%20ECAs%20in%20oncology%20trials%2C%20their%20acceptance%20by%20HTA%20bodies%20remains%20limited.%20Our%20findings%20highlight%20significant%20disparities%20in%20assessment%20approaches%20between%20countries%20and%20persistent%20challenges%20in%20data%20quality%20and%20methodological%20consistency.%20Future%20efforts%20should%20focus%20on%20improving%20transparency%2C%20robustness%2C%20and%20residual%20bias%20assessment%20of%20ECA%20methodologies.%22%2C%22date%22%3A%222025-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41416-025-03155-6%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221532-1827%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A05%3A41Z%22%7D%7D%2C%7B%22key%22%3A%225QIRDI86%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gorostidi%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGorostidi%2C%20Mikel%2C%20Martina%20%26%23xC1%3Bngeles%2C%20Blanca%20Gil-Ib%26%23xE1%3B%26%23xF1%3Bez%2C%20Arantxa%20Lekuona%2C%20Alejandra%20Martinez%2C%20and%20Ignacio%20Zapardiel.%20%26%23x201C%3BSurgical%20Staging%20in%20Locally%20Advanced%20Cervical%20Cancer%3A%20Precision%2C%20Risks%2C%20and%20the%20%26%23x2018%3BHelmet%26%23x2019%3B%20Analogy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2017%2C%20no.%2021%20%28October%2030%2C%202025%29%3A%203487.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers17213487%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers17213487%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Surgical%20Staging%20in%20Locally%20Advanced%20Cervical%20Cancer%3A%20Precision%2C%20Risks%2C%20and%20the%20%5Cu2018Helmet%5Cu2019%20Analogy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikel%22%2C%22lastName%22%3A%22Gorostidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%22%2C%22lastName%22%3A%22%5Cu00c1ngeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blanca%22%2C%22lastName%22%3A%22Gil-Ib%5Cu00e1%5Cu00f1ez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arantxa%22%2C%22lastName%22%3A%22Lekuona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignacio%22%2C%22lastName%22%3A%22Zapardiel%22%7D%5D%2C%22abstractNote%22%3A%22Background%5C%2FObjectives%3A%20This%20study%20aims%20to%20critically%20appraise%20the%20role%20of%20para-aortic%20surgical%20staging%20in%20locally%20advanced%20cervical%20cancer%20%28LACC%29%20in%20the%20era%20of%20advanced%20imaging%2C%20and%20to%20outline%20how%20selective%20surgery%20and%20biomarkers%20could%20be%20integrated%20within%20modern%2C%20quality-assured%20treatment%20pathways.%20Methods%3A%20Narrative%20review%20of%20randomized%20trials%2C%20large%20databases%2C%20and%20prospective%5C%2Fretrospective%20series%20comparing%20para-aortic%20lymphadenectomy%20with%20imaging-based%20staging%3B%20focused%20appraisal%20of%20Uterus-11%2C%20NCDB%20analyses%2C%20and%20ongoing%20prospective%20trials%20%28PAROLA%20with%20Senti-PAROLA%20as%20one%20of%20its%20sub-studies%20and%20PALDISC%29.%20Emerging%20technologies%20%28PET%5C%2FMRI%2C%20radiomics%5C%2FAI%29%20and%20molecular%20assays%20%28OSNA%2C%20HPV-ctDNA%29%20were%20also%20assessed.%20Results%3A%20PET%5C%2FCT%20remains%20the%20standard%20for%20distant%20staging%2C%20but%20sensitivity%20for%20low-volume%20nodal%20disease%20%28%26lt%3B5%20mm%29%20is%20poor%3B%20in%20pelvic-positive%5C%2Fpara-aortic-negative%20patients%2C%20occult%20para-aortic%20metastases%20approach%20~21%25.%20Para-aortic%20surgical%20staging%20modifies%20radiotherapy%20planning%20in%20~18%25%20of%20cases%20and%20can%20act%20as%20a%20de-escalation%20tool%20by%20avoiding%20unnecessary%20extended-field%20CRT%20%28EF-CRT%29%20when%20para-aortic%20nodes%20are%20negative.%20Uterus-11%20showed%20no%20overall%20survival%20difference%20versus%20CT-based%20staging%2C%20but%20suggested%20benefit%20in%20FIGO%202009%20stage%20IIB%3B%20its%20design%20%28CT%20comparator%2C%20optimistic%20assumptions%2C%20limited%20power%29%20constrains%20inference.%20Minimally%20invasive%20extraperitoneal%5C%2Ftransperitoneal%20staging%20is%20feasible%20with%20low%20morbidity%20in%20expert%20centers%2C%20yet%20real-world%20management%20may%20worsen%20outcomes.%20The%20role%20of%20systemic%20intensification%20in%20node-positive%20disease%20remains%20undefined%3A%20PALN-positive%20patients%20were%20excluded%20from%20the%20INTERLACE%20trial.%20In%20the%20KEYNOTE-826%20study%2C%20subgroup%20analyses%20according%20to%20nodal%20status%20were%20not%20reported%2C%20although%20the%20benefit%20of%20pembrolizumab%20remained%20consistent%20irrespective%20of%20bevacizumab%20use.%20Sentinel%20para-aortic%20mapping%20and%20biomarkers%20%28e.g.%2C%20HPV-ctDNA%29%20may%20refine%20selection%20and%20reduce%20morbidity.%20Conclusions%3A%20Surgical%20staging%20is%20the%20most%20accurate%20method%20to%20detect%20occult%20para-aortic%20disease.%20Its%20routine%20use%20is%20not%20justified%2C%20but%20it%20may%20benefit%20selected%20high-risk%20patients%2C%20particularly%20where%20decisions%20on%20EF-CRT%20or%20systemic%20therapy%20hinge%20on%20para-aortic%20status.%20Future%20practice%20should%20integrate%20advanced%20imaging%2C%20selective%20surgery%2C%20and%20biomarkers%20within%20accredited%20centers%2C%20guided%20by%20large%20collaborative%20trials%20conducted%20under%20international%20quality%20frameworks%20such%20as%20ESGO%5C%2FESTRO%5C%2FESP%20guidelines.%22%2C%22date%22%3A%222025-10-30%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers17213487%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F17%5C%2F21%5C%2F3487%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A08%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22R8DKGDC3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonaventura%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBonaventura%2C%20Paola%2C%20Audrey%20Page%2C%20Olivier%20Tabone%2C%20Yann%20Estornes%2C%20Virginie%20Mutez%2C%20Marie%20Delles%2C%20Sarah%20Moran%2C%20et%20al.%20%26%23x201C%3BHERV-Derived%20Epitopes%20Represent%20New%20Targets%20for%20T-Cell-Based%20Immunotherapies%20in%20Ovarian%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20for%20Immunotherapy%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2013%2C%20no.%208%20%28August%203%2C%202025%29%3A%20e010099.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2024-010099%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2024-010099%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HERV-derived%20epitopes%20represent%20new%20targets%20for%20T-cell-based%20immunotherapies%20in%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Bonaventura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Tabone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Estornes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Mutez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Delles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Moran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clarisse%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Richard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjorie%22%2C%22lastName%22%3A%22Lacourr%5Cu00e8ge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dina%20M.%22%2C%22lastName%22%3A%22Tawfik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ema%22%2C%22lastName%22%3A%22Etchegaray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrian%22%2C%22lastName%22%3A%22Valente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rasha%20E.%22%2C%22lastName%22%3A%22Boulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Jimenez%20Dominguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Treilleux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Chopin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Le%20Saux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Chuvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Gadot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qing%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jenny%22%2C%22lastName%22%3A%22Valladeau-Guilemond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Depil%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Ovarian%20cancer%20represents%20the%20most%20lethal%20gynecological%20cancer%20with%20poor%20response%20to%20checkpoint%20inhibitors.%20Human%20endogenous%20retroviruses%20%28HERVs%29%20are%20aberrantly%20expressed%20by%20tumor%20cells%20and%20may%20represent%20a%20source%20of%20shared%20T-cell%20epitopes%20for%20cancer%20immunotherapy%20regardless%20of%20the%20tumor%20mutational%20burden.%5CnMETHODS%3A%20A%20transcriptomic%20analysis%20based%20on%20RNA%20sequencing%20was%20developed%20to%20quantify%20the%20expression%20of%20HERV-K%20sequences%20containing%20the%20selected%20epitopes.%20The%20presence%20of%20HERV-K%5C%2FHML-2%20Gag%20antigen%20was%20then%20assessed%20by%20immunohistochemistry%20%28IHC%29%20on%20tumor%20microarrays%20from%20ovarian%20cancer%20samples%20and%20normal%20ovarian%20tissues.%20A%20specific%20immunopeptidomics%20approach%20was%20developed%20to%20detect%20epitopes%20on%20human%20leukocyte%20antigens%20%28HLA%29%20molecules.%20Epitope-specific%20CD8%2B%20T%20cells%20were%20quantified%20by%20multimer%20staining.%20HERV-specific%20T%20cells%20were%20obtained%20after%20in%20vitro%20stimulation%20of%20T%20cells%20from%20HLA-A2-positive%20healthy%20donors%20or%20patients%20with%20ovarian%20cancer%2C%20and%20in%20vitro%20target%20cell%20killing%20was%20evaluated%20using%20real-time%20analysis.%20In%20vivo%20antitumor%20efficacy%20of%20HERV-specific%20T%20cells%20was%20assessed%20in%20an%20avian%20embryo%20model.%5CnRESULTS%3A%20Epitope-containing%20HERV%20transcripts%20were%20significantly%20higher%20in%20ovarian%20cancers%20compared%20with%20normal%20tissues.%20The%20presence%20of%20the%20HERV-K%5C%2FHML-2%20Gag%20antigen%20was%20confirmed%20by%20IHC%20in%2020%5C%2F40%20%2850%25%29%20ovarian%20cancers%20while%20no%20Gag%20expression%20was%20found%20in%20normal%20ovarian%20tissue%20samples.%20Immunopeptidomics%20analysis%20revealed%20the%20presence%20of%20epitopes%20on%20HLA%20molecules%20on%20the%20surface%20of%20ovarian%20tumor%20cell%20lines%20but%20not%20on%20normal%20primary%20cells%20from%20critical%20tissues.%20Low%20percentages%20of%20HERV-specific%20T%20cells%20were%20detected%20among%20tumor-infiltrating%20lymphocytes%20from%20ovarian%20cancers.%20Furthermore%2C%20in%20vitro%20stimulation%20of%20patient%20T%20cells%20induced%20functional%20epitope-specific%20T%20cells%2C%20confirming%20the%20immunogenicity%20of%20these%20epitopes%20in%20patients%20with%20ovarian%20cancer.%20In%20vitro%2C%20HERV-specific%20T%20cells%20specifically%20killed%20ovarian%20cancer%20cells%20in%20an%20HLA%20class%20I-restricted%20manner%20while%20sparing%20normal%20HLA-A2-positive%20primary%20cells%20derived%20from%20critical%20tissues.%20Epitope-specific%20CD8%2B%20T%20cells%20exhibited%20a%20strong%20antitumoral%20activity%20in%20vivo%2C%20inducing%20a%20highly%20significant%20decrease%20in%20tumor%20volume%20in%20comparison%20with%20control%20groups.%5CnCONCLUSION%3A%20These%20results%20provide%20the%20preclinical%20rationale%20for%20developing%20T-cell-based%20approaches%20against%20HERV-K-derived%20epitopes%20in%20ovarian%20cancer.%22%2C%22date%22%3A%222025-08-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fjitc-2024-010099%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222051-1426%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A04%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22BZY5TYB3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Virazels%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVirazels%2C%20Mathieu%2C%20Am%26%23xE9%3Blie%20Lusque%2C%20St%26%23xE9%3Bphanie%20Brayer%2C%20Matthieu%20Genais%2C%20Carine%20Dufau%2C%20Jean%20Milh%26%23xE8%3Bs%2C%20Thomas%20Filleron%2C%20et%20al.%20%26%23x201C%3BTNF%20Signature%20in%20Advanced%20Melanoma%20Patients%20Treated%20with%20Immune%20Checkpoint%20Inhibitors%3A%20Results%20from%20the%20MELANF%26%23x3B1%3B%20Clinical%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20157%2C%20no.%203%20%28August%201%2C%202025%29%3A%20534%26%23x2013%3B48.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.35416%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.35416%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TNF%20signature%20in%20advanced%20melanoma%20patients%20treated%20with%20immune%20checkpoint%20inhibitors%3A%20Results%20from%20the%20MELANF%5Cu03b1%20clinical%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Virazels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Brayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Genais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Milh%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Sibaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Mortier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Dereure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amandine%22%2C%22lastName%22%3A%22Fabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%5D%2C%22abstractNote%22%3A%22Resistance%20to%20immune%20checkpoint%20inhibitors%20%28ICI%29%20in%20cancer%20patients%20is%20not%20fully%20understood%2C%20and%20predictive%20biomarkers%20are%20lacking.%20MELANF%5Cu03b1%20%28NCT03348891%29%20is%20an%20open-label%2C%20prospective%2C%20multicenter%20cohort%20of%2060%20patients%20with%20advanced%20melanoma%20receiving%20ICI%20%28bitherapy%3A%20ipilimumab%20%2B%20nivolumab%3B%20monotherapy%3A%20pembrolizumab%20or%20nivolumab%29.%20The%20primary%20objective%20was%20to%20evaluate%20whether%20changes%20in%20plasma%20TNF%20between%20baseline%20%28W0%29%20and%20week%2012%20%28W12%29%20identified%20patients%20with%20non-progressive%20disease%20at%20W12.%20Secondary%20and%20exploratory%20objectives%20were%20to%20assess%20the%20association%20between%20plasma%20TNF%2C%20tumor%20response%2C%20and%20changes%20in%20circulating%20T%20cells.%20Plasma%20TNF%20increased%20along%20therapy%2C%20but%20its%20W12%5C%2FW0%20fold%20change%20was%20not%20associated%20with%20non-progressive%20disease%20at%20W12.%20However%2C%20plasma%20TNF%20levels%20at%20W12%20were%20significantly%20higher%20in%20non-responders%20than%20in%20responders%20across%20therapies%20%28p%5Cu2009%3D%5Cu2009.0129%29.%20The%20remodeling%20of%20circulating%20T%20cell%20subpopulations%20was%20mostly%20triggered%20by%20bitherapy.%20Increased%20proportions%20of%20circulating%20central%20memory%20and%20effector%20memory%20CD8%20T%20cells%20after%20bitherapy%20were%20positively%20and%20negatively%20associated%20with%20response%20to%20treatment%2C%20respectively.%20In%20this%20cohort%2C%20circulating%20T%20cells%20from%20responders%20and%20non-responders%20also%20displayed%20distinct%20molecular%20characteristics.%20Indeed%2C%20responders%20showed%20an%20increased%20proportion%20of%20CD8%20T%20cells%20with%20low%20enrichment%20of%20TNF-related%20pathways%20and%20high%20cytotoxic%20potential%2C%20while%20non-responders%20displayed%20increased%20proportions%20of%20circulating%20CD8%20EM%20T%20cells%20enriched%20for%20TNF-related%20pathways%20and%20directed%20toward%20cytokine%20expression.%20In%20conclusion%2C%20our%20study%20shows%20that%20elevated%20plasma%20TNF%20and%20enriched%20TNF%20pathways%20in%20T%20cells%20are%20associated%20with%20poorer%20clinical%20outcomes%2C%20reinforcing%20the%20notion%20that%20TNF%20may%20dampen%20ICI%20efficacy.%22%2C%22date%22%3A%222025-08-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.35416%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221097-0215%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%226FNA338P%22%2C%22FGRJFWV3%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A08%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22UHVEGRZV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Korakis%20et%20al.%22%2C%22parsedDate%22%3A%222025-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKorakis%2C%20I.%2C%20K.%20Ouali%2C%20B.%20Hanvic%2C%20L.%20Verlingue%2C%20B.%20Allignet%2C%20A.%20Lusque%2C%20S.%20Clementei%2C%20et%20al.%20%26%23x201C%3BAddressing%20Screening%20Failures%20in%20Early-Phase%20Clinical%20Trials%20in%20Oncology%3A%20Impact%20on%20Patient%20Outcomes%20and%20Strategies%20for%20Improvement.%26%23x201D%3B%20%26lt%3Bi%26gt%3BESMO%20Open%26lt%3B%5C%2Fi%26gt%3B%2010%2C%20no.%208%20%28August%202025%29%3A%20105331.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2025.105331%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2025.105331%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Addressing%20screening%20failures%20in%20early-phase%20clinical%20trials%20in%20oncology%3A%20impact%20on%20patient%20outcomes%20and%20strategies%20for%20improvement%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Korakis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Ouali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Hanvic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Verlingue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Allignet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Clementei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Magne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Massard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Cassier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Baldini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Segier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Early-phase%20trials%20%28EPT%29%20assess%20efficacy%5C%2Fsafety%20of%20new%20drugs%20that%20may%20represent%20therapeutic%20opportunities.%20Considering%20the%20stringent%20eligibility%20criteria%2C%20the%20screening%20process%20can%20result%20in%20high%20rate%20of%20screen%20failure%20%28SF%29.%20We%20aimed%20to%20identify%20reasons%20for%20SF%20in%20patients%20who%20were%20initially%20deemed%20eligible%20and%20their%20prognostic%20factors.%5CnPATIENTS%20AND%20METHODS%3A%20Patients%20with%20solid%20tumors%20who%20consented%20to%20participate%20in%20EPT%20yet%20screen%20failed%20between%202020%20and%202022%20across%20three%20French%20cancer%20centers%20were%20retrospectively%20included.%20We%20collected%20demographic%20data%2C%20Eastern%20Cooperative%20Oncology%20Group%20%28ECOG%29%20performance%20status%20%28PS%29%2C%20Royal%20Marsden%20Hospital%20%28RMH%29%20score%20upon%20signature%2C%20reason%20for%20SF%20and%20survival%20data.%5CnRESULTS%3A%20A%20total%20of%20202%20patients%20failed%20to%20enroll%20in%20EPT%2C%20representing%20an%20SF%20rate%20of%2021.7%25%20%28Gustave%20Roussy%20Cancer%20Campus%20Villejuif%29%2C%2021.4%25%20%28Oncopole%20Claudius%20Regaud%2C%20Toulouse%29%20and%2026.4%25%20%28Centre%20L%5Cu00e9on%20B%5Cu00e9rard%2C%20Lyon%29.%20Median%20age%20was%2060%20years%20%28range%2020-86%20years%29%3B%20patients%20were%20mainly%20PS1%20%28n%20%3D%20136%2C%2067.3%25%29.%20SF%20reasons%20were%20radiological%20%28n%20%3D%2059%2C%2029.2%25%29%2C%20biological%20%28n%20%3D%2048%2C%2023.8%25%3B%20n%20%3D%2034%20due%20to%20vital%20organ%20dysfunction%29%2C%20clinical%20%28n%20%3D%2045%2C%2022.3%25%29%2C%20administrative%20%28n%20%3D%2022%2C%2010.9%25%29%2C%20and%20PS%20deterioration%20%28n%20%3D%2024%2C%2011.9%25%29%2C%20and%20two%20patients%20died.%20Radiological%20reasons%20included%20brain%20metastases%20%28n%20%3D%2027%29%2C%20nonmeasurable%20disease%20%28n%20%3D%2017%29%20and%20absence%20of%20target%20for%20mandatory%20biopsy%20%28n%20%3D%208%29.%20Three-month%20mortality%20rate%20after%20SF%20was%2030.2%25%2C%20significantly%20related%20to%20biological%20%2826.2%25%29%2C%20clinical%20%2826.2%25%29%20and%20PS%20deterioration%20%2821.3%25%29%20%28P%20%3D%200.012%29.%20Two-thirds%20of%20patients%20with%20newly%20discovered%20brain%20metastases%20were%20alive%20at%203%20months%20%28n%20%3D%2018%5C%2F27%2C%2066.7%25%29.%20Median%20follow-up%20was%2024.6%20months%20%2819.6-26.9%20months%29%2C%206-month%20overall%20survival%20was%2047.5%25%20%284.0-7.1%20months%29.%20In%20the%20multivariable%20analysis%20adjusted%20for%20PS%2C%20location%20of%20metastatic%20sites%20and%20number%20of%20lines%2C%20RMH%20score%20remained%20significantly%20associated%20with%20OS%20%28HR%202.20%2C%20P%20%26lt%3B%200.001%29.%20SF%20patients%20with%20RMH%20score%20of%200-1%20presented%20an%20OS%20close%20to%20enrolled%20patients.%5CnCONCLUSIONS%3A%20Main%20reasons%20for%20SF%20were%20radiological%2C%20biological%20and%20clinical.%20Therefore%2C%20referring%20patients%20with%20brain%20scan%20and%20laboratory%20results%20may%20help%20reduce%20SF%20rates.%20Current%20criteria%20deem%20ineligible%2047.5%25%20of%20patients%20who%20are%20alive%20at%206%20months%2C%20questioning%20their%20accuracy%20for%20patient%20selection%20in%20EPT%20whose%20aim%20is%20to%20evaluate%20drug%20tolerance%5C%2Factivity.%22%2C%22date%22%3A%222025-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2025.105331%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222059-7029%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A05%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22WBG6I66T%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Uppaluri%20et%20al.%22%2C%22parsedDate%22%3A%222025-07-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BUppaluri%2C%20Ravindra%2C%20Robert%20I.%20Haddad%2C%20Yungan%20Tao%2C%20Christophe%20Le%20Tourneau%2C%20Nancy%20Y.%20Lee%2C%20William%20Westra%2C%20Rebecca%20Chernock%2C%20et%20al.%20%26%23x201C%3BNeoadjuvant%20and%20Adjuvant%20Pembrolizumab%20in%20Locally%20Advanced%20Head%20and%20Neck%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20New%20England%20Journal%20of%20Medicine%26lt%3B%5C%2Fi%26gt%3B%20393%2C%20no.%201%20%28July%203%2C%202025%29%3A%2037%26%23x2013%3B50.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMoa2415434%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMoa2415434%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neoadjuvant%20and%20Adjuvant%20Pembrolizumab%20in%20Locally%20Advanced%20Head%20and%20Neck%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ravindra%22%2C%22lastName%22%3A%22Uppaluri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20I.%22%2C%22lastName%22%3A%22Haddad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yungan%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Le%20Tourneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%20Y.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Westra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%22%2C%22lastName%22%3A%22Chernock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Makoto%22%2C%22lastName%22%3A%22Tahara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20J.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arkadiy%20L.%22%2C%22lastName%22%3A%22Klochikhin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irene%22%2C%22lastName%22%3A%22Bra%5Cu00f1a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Vasconcelos%20Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brett%20G.%20M.%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Oliva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iane%22%2C%22lastName%22%3A%22Pinto%20Figueiredo%20Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tsutomu%22%2C%22lastName%22%3A%22Ueda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Rutkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ursula%22%2C%22lastName%22%3A%22Schroeder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul-Stefan%22%2C%22lastName%22%3A%22Mauz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thorsten%22%2C%22lastName%22%3A%22Fuereder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Laban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nobuhiko%22%2C%22lastName%22%3A%22Oridate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aron%22%2C%22lastName%22%3A%22Popovtzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Mach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yevhen%22%2C%22lastName%22%3A%22Korobko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diogo%20Alpuim%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anupama%22%2C%22lastName%22%3A%22Hooda-Nehra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%20P.%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20Bryan%22%2C%22lastName%22%3A%22Bell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cole%22%2C%22lastName%22%3A%22Manschot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberly%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Burak%22%2C%22lastName%22%3A%22Gumuscu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Douglas%22%2C%22lastName%22%3A%22Adkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22KEYNOTE-689%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20benefit%20of%20the%20addition%20of%20perioperative%20pembrolizumab%20to%20standard%20care%20with%20surgery%20and%20adjuvant%20therapy%20for%20patients%20with%20locally%20advanced%20head%20and%20neck%20squamous-cell%20carcinoma%20%28HNSCC%29%20is%20unclear.%5CnMETHODS%3A%20In%20this%20phase%203%2C%20open-label%20trial%2C%20we%20randomly%20assigned%20participants%20with%20locally%20advanced%20HNSCC%20in%20a%201%3A1%20ratio%20to%20receive%202%20cycles%20of%20neoadjuvant%20pembrolizumab%20and%2015%20cycles%20of%20adjuvant%20pembrolizumab%20%28both%20at%20a%20dose%20of%20200%20mg%20every%203%20weeks%29%20in%20addition%20to%20standard%20care%20%28pembrolizumab%20group%29%20or%20standard%20care%20alone%20%28control%20group%29.%20Standard%20care%20was%20surgery%20and%20adjuvant%20radiotherapy%20with%20or%20without%20concomitant%20cisplatin.%20The%20primary%20end%20point%20was%20event-free%20survival%2C%20sequentially%20assessed%20in%20participants%20whose%20tumors%20expressed%20programmed%20death%20ligand%201%20%28PD-L1%29%20with%20a%20combined%20positive%20score%20%28CPS%29%20of%2010%20or%20more%20%28CPS-10%20population%29%2C%20participants%20whose%20tumors%20expressed%20PD-L1%20with%20a%20CPS%20of%201%20or%20more%20%28CPS-1%20population%29%2C%20and%20all%20the%20participants.%20A%20higher%20CPS%20indicates%20a%20higher%20proportion%20of%20cells%20that%20express%20PD-L1.%5CnRESULTS%3A%20A%20total%20of%20363%20participants%20%28234%20with%20a%20CPS%20of%20%5Cu226510%20and%20347%20with%20a%20CPS%20of%20%5Cu22651%29%20were%20assigned%20to%20the%20pembrolizumab%20group%20and%20351%20%28231%20with%20a%20CPS%20of%20%5Cu226510%20and%20335%20with%20a%20CPS%20of%20%5Cu22651%29%20to%20the%20control%20group.%20Surgery%20was%20completed%20in%20approximately%2088%25%20of%20the%20participants%20in%20each%20group.%20At%20the%20first%20interim%20analysis%2C%20the%20median%20follow-up%20was%2038.3%20months.%20Event-free%20survival%20at%2036%20months%20was%2059.8%25%20in%20the%20pembrolizumab%20group%20and%2045.9%25%20in%20the%20control%20group%20%28hazard%20ratio%20for%20progression%2C%20recurrence%2C%20or%20death%2C%200.66%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%200.49%20to%200.88%3B%20two-sided%20P%5Cu2009%3D%5Cu20090.004%29%20in%20the%20CPS-10%20population%3B%2058.2%25%20and%2044.9%25%2C%20respectively%20%28hazard%20ratio%2C%200.70%3B%2095%25%20CI%2C%200.55%20to%200.89%3B%20two-sided%20P%5Cu2009%3D%5Cu20090.003%29%2C%20in%20the%20CPS-1%20population%3B%20and%2057.6%25%20and%2046.4%25%2C%20respectively%20%28hazard%20ratio%2C%200.73%3B%2095%25%20CI%2C%200.58%20to%200.92%3B%20two-sided%20P%5Cu2009%3D%5Cu20090.008%29%2C%20in%20the%20total%20population.%20Grade%203%20or%20higher%20treatment-related%20adverse%20events%20occurred%20in%2044.6%25%20of%20the%20participants%20in%20the%20pembrolizumab%20group%20and%20in%2042.9%25%20of%20those%20in%20the%20control%20group%2C%20including%20death%20in%201.1%25%20and%200.3%25%2C%20respectively.%20Potentially%20immune-mediated%20adverse%20events%20of%20grade%203%20or%20higher%20occurred%20in%2010.0%25%20of%20the%20participants%20in%20the%20pembrolizumab%20group.%5CnCONCLUSIONS%3A%20The%20addition%20of%20neoadjuvant%20and%20adjuvant%20pembrolizumab%20to%20standard%20care%20significantly%20improved%20event-free%20survival%20among%20participants%20with%20locally%20advanced%20HNSCC.%20Neoadjuvant%20pembrolizumab%20did%20not%20affect%20the%20likelihood%20of%20surgical%20completion.%20No%20new%20safety%20signals%20were%20identified.%20%28Funded%20by%20Merck%20Sharp%20and%20Dohme%2C%20a%20subsidiary%20of%20Merck%20%5BRahway%2C%20NJ%5D%3B%20KEYNOTE-689%20ClinicalTrials.gov%20number%2C%20NCT03765918.%29.%22%2C%22date%22%3A%222025-07-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa2415434%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221533-4406%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A06%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22EQXVUFKR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Modesto%20et%20al.%22%2C%22parsedDate%22%3A%222025-06-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BModesto%2C%20Anouchka%2C%20Sophie%20Gibert%2C%20Caroline%20Delmas%2C%20David%20Tougeron%2C%20Amaury%20Paumier%2C%20Alexandre%20Taillez%2C%20Samuel%20Le%20Sourd%2C%20et%20al.%20%26%23x201C%3BSizing%20and%20Concentration%20Analysis%20of%20cfDNA%20Using%20Biabooster%20Technology%3A%20Results%20from%20a%20Prospective%20Plasma-Based%20Collection%20of%2077%20Patients%20with%20Locally%20Advanced%20Unresectable%20Esophageal%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20June%2020%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70011%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70011%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sizing%20and%20concentration%20analysis%20of%20cfDNA%20using%20Biabooster%20technology%3A%20Results%20from%20a%20prospective%20plasma-based%20collection%20of%2077%20patients%20with%20locally%20advanced%20unresectable%20esophageal%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anouchka%22%2C%22lastName%22%3A%22Modesto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Gibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Tougeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amaury%22%2C%22lastName%22%3A%22Paumier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Taillez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Le%20Sourd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%20Argo%22%2C%22lastName%22%3A%22Leignel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Ronchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariane%20Darut%22%2C%22lastName%22%3A%22Jouve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Vendrely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Riou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Martin-Babau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Qu%5Cu00e9ro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efma%22%2C%22lastName%22%3A%22Hanoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronica%22%2C%22lastName%22%3A%22Pezzella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Moyal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Seva%22%7D%5D%2C%22abstractNote%22%3A%22Locally%20advanced%20esophageal%20carcinoma%20remains%20of%20poor%20prognosis%20correlated%20with%20tumor%20stage.%20Albeit%20liquid%20biopsy%20approach%20offers%20promising%20results%20to%20monitor%20high-risk%20patients%20in%20various%20solid%20tumors%2C%20the%20lack%20of%20specific%20mutation%20in%20esophageal%20tumor%2C%20limits%20the%20detection%20of%20circulating%20tumor%20DNA%20%28ctDNA%29%20with%20high%20sensitivity%20using%20sequencing-based%20methods.%20In%20this%20study%2C%20we%20employed%20a%20highly%20sensitive%20technology%20of%20fragmentome%20assay%2C%20previously%20validated%20to%20measure%20concentration%20and%20size%20distribution%20of%20cell-free%20DNA%20%28cfDNA%29%2C%20to%20analyze%20plasma%20samples%20from%2077%20patients%20with%20esophageal%20carcinoma%2C%20compared%20to%2015%20healthy%20controls.%20Total%20cfDNA%20concentration%20was%20significantly%20higher%20in%20patients%20than%20in%20healthy%20donors%20%2815.03%5Cu2009%5Cu00b1%5Cu20091.37%20vs.%205.87%5Cu2009%5Cu00b1%5Cu20090.85%5Cu2009pg%5C%2F%5Cu03bcL%2C%20p%5Cu2009%26lt%3B%5Cu2009.0001%29.%20The%20difference%20remained%20significant%20regardless%20of%20tumor%20histology%2C%20location%2C%20stage%2C%20or%20nodal%20involvement%20and%20was%20independent%20from%20age%20or%20gender.%20Additionally%2C%20we%20observed%20a%20significant%20reduction%20in%20patients%20fragment%20length%20compared%20to%20healthy%20donors.%20The%20area%20under%20curve%20from%20receiver%20operating%20characteristic%20%28ROC%29%20of%20total%20cfDNA%20concentration%20in%20patients%20versus%20healthy%20donors%20was%200.86%20%28p-value%20%26lt%3B.0001%29.%20The%20threshold%20of%207.5%5Cu2009pg%5C%2F%5Cu03bcL%20yielded%20a%20sensitivity%20of%2081%25%20and%20a%20specificity%20of%2080%25.%20This%20prospective%20study%20demonstrated%20that%20blood%20samples%20from%20patients%20exhibit%20a%20greater%20global%20concentration%20of%20smaller%20fragments%20compared%20to%20healthy%20controls.%20These%20findings%20support%20further%20longitudinal%20evaluation%20to%20determine%20the%20predictive%20and%20prognostic%20value%20of%20cfDNA%20in%20locally%20advanced%20unresectable%20esophageal%20carcinoma.%22%2C%22date%22%3A%222025-06-20%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.70011%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221097-0215%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%226BDVTCJV%22%2C%22FGRJFWV3%22%2C%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A08%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22HBYKYTCB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alsugair%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAlsugair%2C%20Ziyad%2C%20Charles%20L%26%23xE9%3Bpine%2C%20Maxime%20Fieux%2C%20Fran%26%23xE7%3Boise%20Descotes%2C%20Daniel%20Pissaloux%2C%20Jonathan%20Lopez%2C%20Juliette%20Russel%2C%20et%20al.%20%26%23x201C%3BUnderstanding%20and%20Overcoming%20the%20Pitfalls%20in%20the%20Diagnosis%20of%20Pleomorphic%20and%20Carcinoma%20Ex-Pleomorphic%20Adenoma%20of%20Salivary%20Glands.%26%23x201D%3B%20%26lt%3Bi%26gt%3BHistopathology%26lt%3B%5C%2Fi%26gt%3B%2086%2C%20no.%206%20%28May%202025%29%3A%201013%26%23x2013%3B16.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.15392%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhis.15392%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Understanding%20and%20overcoming%20the%20pitfalls%20in%20the%20diagnosis%20of%20pleomorphic%20and%20carcinoma%20ex-pleomorphic%20adenoma%20of%20salivary%20glands%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ziyad%22%2C%22lastName%22%3A%22Alsugair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22L%5Cu00e9pine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Fieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Descotes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Pissaloux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Russel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22C%5Cu00e9ruse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Philouze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Uro-Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Costes-Martineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Champagnac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nazim%22%2C%22lastName%22%3A%22Benzerdjeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22REFCOR%20network%22%7D%5D%2C%22abstractNote%22%3A%22The%20study%20illustrates%20a%20recurrent%20pitfall%20in%20the%20diagnosis%20of%20pleomorphic%20adenoma%20and%20carcinoma%20ex%20pleomorphic%20adenoma.%22%2C%22date%22%3A%222025-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fhis.15392%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221365-2559%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A06%3A54Z%22%7D%7D%2C%7B%22key%22%3A%228TSE7I7F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tr%5Cu00e9dan%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTr%26%23xE9%3Bdan%2C%20Olivier%2C%20Damien%20Pouessel%2C%20Nicolas%20Penel%2C%20Sylvie%20Chabaud%2C%20Carlos%20Gomez-Roca%2C%20Jean-Pierre%20Delord%2C%20Diane%20Pannier%2C%20et%20al.%20%26%23x201C%3BBroad%20versus%20Limited%20Gene%20Panels%20to%20Guide%20Treatment%20in%20Patients%20with%20Advanced%20Solid%20Tumors%3A%20A%20Randomized%20Controlled%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNature%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2031%2C%20no.%205%20%28May%202025%29%3A%201502%26%23x2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-025-03613-x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41591-025-03613-x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Broad%20versus%20limited%20gene%20panels%20to%20guide%20treatment%20in%20patients%20with%20advanced%20solid%20tumors%3A%20a%20randomized%20controlled%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Tr%5Cu00e9dan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Pouessel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Chabaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Pannier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Fabbro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Eve%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Larrieu-Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Ray-Coquard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Viala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%22%2C%22lastName%22%3A%22Tosi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cassier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armelle%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valery%22%2C%22lastName%22%3A%22Attignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Boyault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Treilleux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Viari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22P%5Cu00e9rol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Yves%22%2C%22lastName%22%3A%22Blay%22%7D%5D%2C%22abstractNote%22%3A%22Large%20genomic%20programs%20have%20contributed%20to%20improving%20drug%20development%20in%20cancer.%20To%20assess%20the%20potential%20benefit%20of%20using%20larger%20gene%20panels%20to%20guide%20molecular-based%20treatments%2C%20we%20conducted%20a%20multicenter%20randomized%20trial%20in%20patients%20with%20advanced%20and%5C%2For%20metastatic%20solid%20cancer.%20Molecular%20alterations%20were%20determined%20using%20either%20a%20panel%20of%20324%20cancer-related%20genes%20%28Foundation%20OneCDX%20%28F1CDX%29%29%20or%20a%20limited%20panel%20of%2087%20single-nucleotide%5C%2Findel%20genes%20and%20genome-wide%20copy%20number%20variations%20%28CTL%29%20and%20reviewed%20by%20a%20molecular%20tumor%20board%20to%20identify%20molecular-based%20recommended%20therapies%20%28MBRTs%29.%20Using%20paired%20data%20from%20both%20panels%20for%20each%20patient%2C%20the%20primary%20endpoint%20was%20the%20proportion%20of%20patients%20with%20an%20MBRT%20identified.%20Main%20secondary%20endpoints%20included%20the%20number%20of%20patients%20with%20at%20least%20one%20actionable%20alteration%20leading%20to%20MBRT%20identification%2C%20the%20number%20of%20patients%20with%20and%20without%20MBRTs%20initiated%2C%20progression-free%20survival%2C%20best%20overall%20response%2C%20duration%20of%20response%20and%20safety.%20Among%20the%20741%20patients%20screened%2C%2045.7%25%20had%20quality-checked%20tumor%20samples.%20MBRTs%20were%20identified%20with%20F1CDX%20in%20175%20%2851.6%25%29%20patients%20and%20with%20CTL%20in%20125%20%2836.9%25%29%20patients%2C%20translating%20to%20a%20significant%20increase%20of%2014.8%20percentage%20points%20%28P%5Cu2009%26lt%3B%5Cu20090.001%29%20with%20the%20more%20comprehensive%20gene%20panel%20versus%20the%20more%20limited%20panel%2C%20meeting%20the%20primary%20endpoint.%20However%2C%20no%20differences%20in%20clinical%20outcomes%20were%20observed%20in%20these%20patients%20with%20advanced%20and%5C%2For%20metastatic%20cancer%20in%20need%20of%20treatment%20beyond%20standard%20genomic%20alterations.%20These%20findings%20illustrate%20the%20potential%20for%20larger%20gene%20panels%20to%20increase%20the%20number%20of%20molecularly%20matched%20therapies.%20Larger%20studies%20are%20needed%20to%20assess%20the%20clinical%20benefit%20of%20expanded%20MBRTs.%20ClinicalTrials.gov%20registration%3A%20NCT03163732%20.%22%2C%22date%22%3A%222025-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41591-025-03613-x%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221546-170X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A06%3A40Z%22%7D%7D%2C%7B%22key%22%3A%2264IIUG2P%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bizzarri%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBizzarri%2C%20Nicol%26%23xF2%3B%2C%20Denis%20Querleu%2C%20Giulio%20Ricotta%2C%20Diana%20Giannarelli%2C%20Mihai%20Emil%20C%26%23xE3%3Bp%26%23xEE%3Blna%2C%20Santiago%20Domingo%2C%20Vito%20Chiantera%2C%20et%20al.%20%26%23x201C%3BComplications%20and%20Recurrence%20After%20Pelvic%20Exenteration%20for%20Gynecologic%20Malignancies%3A%20Survival%20Analysis%20From%20the%20COREPEX%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BObstetrics%20%26amp%3B%20Gynecology%26lt%3B%5C%2Fi%26gt%3B%20146%2C%20no.%205%20%282025%29%3A%20737%26%23x2013%3B49.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FAOG.0000000000006051%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FAOG.0000000000006051%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Complications%20and%20Recurrence%20After%20Pelvic%20Exenteration%20for%20Gynecologic%20Malignancies%3A%20Survival%20Analysis%20From%20the%20COREPEX%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicol%5Cu00f2%22%2C%22lastName%22%3A%22Bizzarri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%22%2C%22lastName%22%3A%22Ricotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Giannarelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihai%20Emil%22%2C%22lastName%22%3A%22C%5Cu00e3p%5Cu00eelna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%22%2C%22lastName%22%3A%22Domingo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vito%22%2C%22lastName%22%3A%22Chiantera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00fcseyin%22%2C%22lastName%22%3A%22Ak%5Cu0131ll%5Cu0131%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cibula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoltan%22%2C%22lastName%22%3A%22Nov%5Cu00e1k%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Zach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Miranda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Porfyrios%22%2C%22lastName%22%3A%22Korompelis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrique%22%2C%22lastName%22%3A%22Chacon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignacio%22%2C%22lastName%22%3A%22Zapardiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bj%5Cu00f6rn%22%2C%22lastName%22%3A%22Lampe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentyn%22%2C%22lastName%22%3A%22Svintsitskyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Matylevich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabrielle%20H.%22%2C%22lastName%22%3A%22Van%20Ramshorst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cagatay%22%2C%22lastName%22%3A%22Taskiran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fuat%22%2C%22lastName%22%3A%22Demirk%5Cu0131ran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tibor%22%2C%22lastName%22%3A%22Lengyel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Vizzielli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matteo%22%2C%22lastName%22%3A%22Loverro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gauroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Ladanyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Szilard%20Leo%22%2C%22lastName%22%3A%22Kiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Lago%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manel%22%2C%22lastName%22%3A%22Montesinos-Albert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariano%20Catello%22%2C%22lastName%22%3A%22Di%20Donna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Cucinella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Ayhan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiri%22%2C%22lastName%22%3A%22Slama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vikt%5Cu00f3ria%22%2C%22lastName%22%3A%22Rosta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahar%22%2C%22lastName%22%3A%22Salehi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mustafa%20Zelal%22%2C%22lastName%22%3A%22Muallem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ali%22%2C%22lastName%22%3A%22Kucukmetin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Scambia%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20To%20collect%20data%20from%20patients%20undergoing%20pelvic%20exenteration%20in%20recent%20clinical%20practice.%20The%20primary%20aim%20was%205-year%20disease-free%20survival.%20Secondary%20aims%20were%205-year%20overall%20survival%2C%20patterns%20of%20recurrence%2C%20identification%20of%20subgroups%20at%20higher%20risk%20of%20recurrence%20and%20death%2C%20survival%20associated%20with%20lymph%20node%20metastasis%2C%20and%20development%20of%20a%20prognostic%20score.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20METHODS%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20was%20a%20retrospective%2C%20multicenter%2C%20international%20study%20conducted%20in%20tertiary%20national%20gynecologic%20oncology%20referral%20centers.%20Inclusion%20criteria%20included%20cervical%2C%20vaginal%2C%20vulvar%2C%20or%20endometrial%20cancer%3B%20anterior%20or%20total%20pelvic%20exenteration%20performed%20between%20January%202005%20and%20March%202023%3B%20curative%20or%20palliative%20intent%3B%20and%20with%20or%20without%20laterally%20extended%20endopelvic%20or%20pelvic%20resection.%20Patients%20were%20excluded%20if%20they%20underwent%20posterior%20pelvic%20exenteration%20only%20or%20if%20preoperative%20computed%20tomography%20%28CT%29%2C%20positron%20emission%20tomography%20%28PET%29%5Cu2013CT%2C%20or%20PET%20was%20not%20performed.%20A%20prognostic%20score%20was%20developed%20that%20was%20based%20on%20multivariable%20analysis.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20RESULTS%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20Eight%20hundred%20sixty-two%20patients%20were%20included.%20Surgical%20margins%20were%20tumor%20free%20in%20676%20%2878.4%25%29.%20In%20patients%20treated%20with%20curative%20intent%2C%20total%20pelvic%20exenteration%2C%20positive%20surgical%20margins%2C%20and%20presence%20of%20lymphovascular%20space%20invasion%20were%20independently%20associated%20with%20worse%20disease-free%20survival.%20Performance%20of%20lymphadenectomy%20was%20associated%20with%20better%20disease-free%20survival.%20Total%20pelvic%20exenteration%2C%20positive%20surgical%20margins%2C%20and%20presence%20of%20lymphovascular%20space%20invasion%20were%20factors%20independently%20associated%20with%20decreased%20overall%20survival.%20Performing%20pelvic%20exenteration%20at%20time%20of%20persistent%20%28instead%20of%20recurrent%29%20disease%20negatively%20affected%20overall%20survival.%20Prognostic%20score%20identified%20four%20risk%20groups%20with%20a%205-year%20disease-free%20survival%20of%2043.7%25%2C%2024.9%25%2C%2022.2%25%2C%20and%208.0%25%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%26lt%3B.001%29.%20The%205-year%20overall%20survival%20in%20the%20four%20risk%20groups%20was%2054.3%25%2C%2040.4%25%2C%2024.0%25%2C%20and%204.3%25%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%26lt%3B.001%29.%20The%20most%20frequent%20sites%20of%20recurrence%20were%20distant%20in%20166%20patients%20%2832.1%25%29.%20The%205-year%20disease-free%20survival%20and%20cancer-specific%20survival%20in%20patients%20with%20para-aortic%20lymph%20node%20metastasis%20were%20significantly%20worse%20compared%20with%20those%20in%20patients%20with%20pelvic-only%20metastatic%20nodes%20or%20with%20negative%20nodes%20%28%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3D.002%20and%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20P%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%26lt%3B.001%2C%20respectively%29.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20CONCLUSION%3A%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Independent%20factors%20associated%20with%20worse%20disease-free%20survival%20and%20overall%20survival%20and%20subgroups%20of%20patients%20at%20higher%20risk%20of%20recurrence%20and%20death%20were%20identified.%20A%20multivariable%20prognostic%20score%20was%20developed%20that%20can%20be%20used%20for%20patient%20counseling%20and%20surveillance%20strategies%20and%20for%20future%20prospective%20studies.%22%2C%22date%22%3A%2211%5C%2F2025%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FAOG.0000000000006051%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2F10.1097%5C%2FAOG.0000000000006051%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220029-7844%2C%201873-233X%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A08%3A06Z%22%7D%7D%2C%7B%22key%22%3A%226AP4FL9C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Machiels%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMachiels%2C%20J.-P.%2C%20Y.%20Tao%2C%20L.%20Licitra%2C%20B.%20Burtness%2C%20M.%20Tahara%2C%20D.%20Rischin%2C%20G.%20V.%20Alves%2C%20et%20al.%20%26%23x201C%3BHealth-Related%20Quality%20of%20Life%20Outcomes%20from%20KEYNOTE-412%3A%20Chemoradiotherapy%20with%20or%20without%20Pembrolizumab%20in%20Participants%20with%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2015%20%282025%29%3A%201645509.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2025.1645509%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2025.1645509%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Health-related%20quality%20of%20life%20outcomes%20from%20KEYNOTE-412%3A%20chemoradiotherapy%20with%20or%20without%20pembrolizumab%20in%20participants%20with%20head%20and%20neck%20squamous%20cell%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Machiels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Licitra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Burtness%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Tahara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Rischin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20V.%22%2C%22lastName%22%3A%22Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20P.%20F.%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20G.%20M.%22%2C%22lastName%22%3A%22Hughes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Pointreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Aksoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Laban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Greil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Burian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Hetnal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Mesia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Taberna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Waldron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Gregoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Harrington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20M.%22%2C%22lastName%22%3A%22Black%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Norquist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Gumuscu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Bidadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20L.%22%2C%22lastName%22%3A%22Siu%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20health-related%20quality%20of%20life%20%28HRQoL%29%20of%20patients%20with%20locally%20advanced%20head%20and%20neck%20squamous%20cell%20carcinoma%20%28LA%20HNSCC%29%20is%20impacted%20by%20both%20disease-%20and%20treatment-related%20factors.%20Treatments%20that%20preserve%20and%20maximize%20HRQoL%20in%20this%20setting%20represent%20a%20substantial%20unmet%20need.%5CnMETHODS%3A%20KEYNOTE-412%20%28NCT03040999%29%20was%20a%20randomized%2C%20double-blind%2C%20placebo-controlled%20phase%203%20study%20of%20pembrolizumab%20plus%20chemoradiotherapy%20%28CRT%29%20versus%20placebo%20plus%20CRT%20for%20maintenance%20therapy%20in%20participants%20with%20treatment-na%5Cu00efve%20LA%20HNSCC.%20Patient-reported%20outcomes%20%28PROs%29%20assessed%20using%20the%20European%20Organisation%20for%20Research%20and%20Treatment%20of%20Cancer%20Quality%20of%20Life%20Questionnaire%20Core%2030%20%28EORTC%20QLQ-C30%29%20and%20EORTC%20QLQ%20Head%20and%20Neck%2035%20%28H%26amp%3BN35%29%20were%20pre-specified%20secondary%20endpoints%20and%20administered%20at%20baseline%20and%20throughout%20the%20study.%20Least%20squares%20mean%20%28LSM%29%20change%20from%20baseline%20was%20assessed%20using%20a%20constrained%20longitudinal%20data%20analysis%20model.%20No%20formal%20statistical%20significance%20testing%20was%20performed.%5CnRESULTS%3A%20The%20PRO%20analysis%20population%20included%20395%20participants%20randomized%20to%20receive%20pembrolizumab%20plus%20CRT%20and%20397%20to%20receive%20placebo%20plus%20CRT.%20Completion%20rates%20for%20all%20assessed%20PROs%20were%20%26gt%3B95%25%20at%20baseline%20and%20%26gt%3B66%25%20at%20week%2045.%20LSM%20change%20from%20baseline%20to%20week%2045%20was%20similar%20between%20groups%20across%20EORTC%20QLQ-C30%20and%20QLQ-H%26amp%3BN35%20subscale%20scores.%20There%20were%20no%20notable%20differences%20in%20empirical%20mean%20change%20or%20the%20proportion%20of%20participants%20with%20improvement%2C%20stability%2C%20or%20deterioration%20from%20baseline%20to%20week%2045%20between%20treatment%20groups.%5CnCONCLUSION%3A%20The%20addition%20of%20pembrolizumab%20to%20CRT%20did%20not%20meaningfully%20impact%20HRQoL%20in%20participants%20with%20LA%20HNSCC.%22%2C%22date%22%3A%222025%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffonc.2025.1645509%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222234-943X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A05%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22Y9FMX84K%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Scarlata%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BScarlata%2C%20Clara-Maria%2C%20Virginie%20Feliu%2C%20Christel%20Devaud%2C%20and%20Maha%20Ayyoub.%20%26%23x201C%3BAssessment%20of%20Human%20and%20Mouse%20Tumor-Antigen%20Specific%20CD8%26%23xA0%3B%2B%26%23xA0%3BT%20Cells%20by%20Multimer%20Staining%20in%20Multiple%20Compartments.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMethods%20in%20Cell%20Biology%26lt%3B%5C%2Fi%26gt%3B%20199%20%282025%29%3A%20145%26%23x2013%3B59.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fbs.mcb.2025.03.028%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fbs.mcb.2025.03.028%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessment%20of%20human%20and%20mouse%20tumor-antigen%20specific%20CD8%5Cu00a0%2B%5Cu00a0T%20cells%20by%20multimer%20staining%20in%20multiple%20compartments%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Feliu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%5D%2C%22abstractNote%22%3A%22Detection%20of%20tumor%20antigen-specific%20T%20cells%20at%20the%20tumor%20site%20and%20in%20the%20periphery%20is%20pivotal%20to%20study%20and%20monitor%20T%20cells%20directly%20involved%20in%20the%20antitumor%20immune%20response.%20Through%20their%20T-cell%20receptor%20%28TCR%29%2C%20T%20cells%20recognize%20tumor%20cells%20presenting%20their%20antigenic%20peptides%20by%20major%20histocompatibility%20complex%20%28MHC%29%20molecules.%20Analyses%20of%20antigen-specific%20CD8%2B%20and%20CD4%2B%20T%20cells%20can%20be%20realized%20by%20flow%20cytometry%2C%20using%20fluorochrome-conjugated%20multiplexed%20peptide-MHC%20molecules.%20These%20peptide-MHC%20multimers%2C%20in%20conjunction%20with%20continuing%20advances%20in%20flow%20cytometry%2C%20have%20transformed%20the%20characterization%20of%20antigen-specific%20T%20cells.%20They%20enable%20the%20visualization%2C%20enumeration%2C%20tracking%2C%20phenotype%20characterization%20and%20isolation%20of%20T%20cells%20during%20infection%2C%20autoimmunity%20and%20cancer.%20They%20can%20be%20useful%20to%20monitor%20specific%20adaptive%20responses%20during%20various%20type%20of%20therapies.%20Here%20we%20detail%20a%20simple%20and%20accurate%20protocol%20of%20multimer%20staining%20of%20tumor%20antigen-specific%20CD8%2B%20T%20cells%20isolated%20from%20human%20and%20mouse%20tumors%20and%20Peripheral%20Blood%20Mononuclear%20Cells%20%28PBMCs%29.%22%2C%22date%22%3A%222025%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fbs.mcb.2025.03.028%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220091-679X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222026-03-27T08%3A05%3A07Z%22%7D%7D%5D%7D
Monnereau, Matthias, Jean-Pierre Delord, Stefan Michiels, Christophe Le Tourneau, Sebastien Marque, Louise Baschet, and Thomas Filleron. “Acceptance of External Control Arms by HTA Agencies: A Review of Oncology Submissions in France, England, Germany and Norway from 2021 to 2023.” British Journal of Cancer 133, no. 10 (November 2025): 1501–7. https://doi.org/10.1038/s41416-025-03155-6.
Gorostidi, Mikel, Martina Ángeles, Blanca Gil-Ibáñez, Arantxa Lekuona, Alejandra Martinez, and Ignacio Zapardiel. “Surgical Staging in Locally Advanced Cervical Cancer: Precision, Risks, and the ‘Helmet’ Analogy.” Cancers 17, no. 21 (October 30, 2025): 3487. https://doi.org/10.3390/cancers17213487.
Bonaventura, Paola, Audrey Page, Olivier Tabone, Yann Estornes, Virginie Mutez, Marie Delles, Sarah Moran, et al. “HERV-Derived Epitopes Represent New Targets for T-Cell-Based Immunotherapies in Ovarian Cancer.” Journal for Immunotherapy of Cancer 13, no. 8 (August 3, 2025): e010099. https://doi.org/10.1136/jitc-2024-010099.
Virazels, Mathieu, Amélie Lusque, Stéphanie Brayer, Matthieu Genais, Carine Dufau, Jean Milhès, Thomas Filleron, et al. “TNF Signature in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors: Results from the MELANFα Clinical Study.” International Journal of Cancer 157, no. 3 (August 1, 2025): 534–48. https://doi.org/10.1002/ijc.35416.
Korakis, I., K. Ouali, B. Hanvic, L. Verlingue, B. Allignet, A. Lusque, S. Clementei, et al. “Addressing Screening Failures in Early-Phase Clinical Trials in Oncology: Impact on Patient Outcomes and Strategies for Improvement.” ESMO Open 10, no. 8 (August 2025): 105331. https://doi.org/10.1016/j.esmoop.2025.105331.
Uppaluri, Ravindra, Robert I. Haddad, Yungan Tao, Christophe Le Tourneau, Nancy Y. Lee, William Westra, Rebecca Chernock, et al. “Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.” The New England Journal of Medicine 393, no. 1 (July 3, 2025): 37–50. https://doi.org/10.1056/NEJMoa2415434.
Modesto, Anouchka, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, et al. “Sizing and Concentration Analysis of cfDNA Using Biabooster Technology: Results from a Prospective Plasma-Based Collection of 77 Patients with Locally Advanced Unresectable Esophageal Cancer.” International Journal of Cancer, June 20, 2025. https://doi.org/10.1002/ijc.70011.
Alsugair, Ziyad, Charles Lépine, Maxime Fieux, Françoise Descotes, Daniel Pissaloux, Jonathan Lopez, Juliette Russel, et al. “Understanding and Overcoming the Pitfalls in the Diagnosis of Pleomorphic and Carcinoma Ex-Pleomorphic Adenoma of Salivary Glands.” Histopathology 86, no. 6 (May 2025): 1013–16. https://doi.org/10.1111/his.15392.
Trédan, Olivier, Damien Pouessel, Nicolas Penel, Sylvie Chabaud, Carlos Gomez-Roca, Jean-Pierre Delord, Diane Pannier, et al. “Broad versus Limited Gene Panels to Guide Treatment in Patients with Advanced Solid Tumors: A Randomized Controlled Trial.” Nature Medicine 31, no. 5 (May 2025): 1502–8. https://doi.org/10.1038/s41591-025-03613-x.
Bizzarri, Nicolò, Denis Querleu, Giulio Ricotta, Diana Giannarelli, Mihai Emil Cãpîlna, Santiago Domingo, Vito Chiantera, et al. “Complications and Recurrence After Pelvic Exenteration for Gynecologic Malignancies: Survival Analysis From the COREPEX Study.” Obstetrics & Gynecology 146, no. 5 (2025): 737–49. https://doi.org/10.1097/AOG.0000000000006051.
Machiels, J.-P., Y. Tao, L. Licitra, B. Burtness, M. Tahara, D. Rischin, G. V. Alves, et al. “Health-Related Quality of Life Outcomes from KEYNOTE-412: Chemoradiotherapy with or without Pembrolizumab in Participants with Head and Neck Squamous Cell Carcinoma.” Frontiers in Oncology 15 (2025): 1645509. https://doi.org/10.3389/fonc.2025.1645509.
Scarlata, Clara-Maria, Virginie Feliu, Christel Devaud, and Maha Ayyoub. “Assessment of Human and Mouse Tumor-Antigen Specific CD8 + T Cells by Multimer Staining in Multiple Compartments.” Methods in Cell Biology 199 (2025): 145–59. https://doi.org/10.1016/bs.mcb.2025.03.028.
PUBLICATIONS 2024
7813506
FGRJFWV3
2024
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22NK4DV4HY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Del%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDel%2C%20Mathilde%2C%20Claire%20Illac%2C%20Mathilde%20Morisseau%2C%20Martina%20Aida%20Angeles%2C%20Anne%20Ducassou%2C%20Sarah%20Betrian%2C%20Guillaume%20Bataillon%2C%20et%20al.%20%26%23x201C%3BIntraepithelial%20Tumor-Infiltrating%20Lymphocytes%20Shape%20Loco-Regional%20PET%5C%2FCT%20Spread%20of%20Locally%20Advanced%20Cervical%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2034%2C%20no.%204%20%28April%201%2C%202024%29%3A%20490%26%23x2013%3B96.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2023-004677%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2023-004677%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intraepithelial%20tumor-infiltrating%20lymphocytes%20shape%20loco-regional%20PET%5C%2FCT%20spread%20of%20locally%20advanced%20cervical%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Del%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Illac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Morisseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Betrian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Bataillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Chantalat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Gabiache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Data%20suggest%20an%20association%20between%20positron%20emission%20tomography%5C%2FCT%20%28PET%5C%2FCT%29%20metabolic%20metrics%20and%20tumor%20microenvironment%20in%20several%20malignancies%2C%20and%20a%20potential%20role%20of%20PET%5C%2FCT%20to%20monitor%20response%20to%20immunotherapy.%5CnOBJECTIVE%3A%20To%20evaluate%20the%20correlation%20between%20tumor%20loco-regional%20extension%20and%20tumor-infiltrating%20lymphocyte%20infiltration%20in%20locally%20advanced%20cervical%20cancer%20prior%20to%20concurrent%20chemo-radiotherapy.The%20secondary%20objective%20was%20to%20assess%20the%20association%20between%20tumor-infiltrating%20lymphocytes%20and%20PET%5C%2FCT%20metabolic%20metrics.%5CnMETHODS%3A%20Patients%20with%20locally%20advanced%20cervical%20cancer%20and%20negative%20para-aortic%20extensions%20on%20PET%5C%2FCT%20were%20included.%20Two%20senior%20nuclear%20medicine%20physicians%20specializing%20in%20gynecologic%20oncology%20reviewed%20all%20PET%5C%2FCT%20exams%2C%20and%20extracted%20tumor%20maximum%20standardized%20uptake%20value%2C%20metabolic%20tumor%20volume%2C%20and%20total%20lesion%20glycolysis%2C%20as%20well%20as%20pelvic%20lymph%20node%20involvement.%20One%20senior%20gynecologic%20oncology%20pathologist%20assessed%20intraepithelial%20tumor-infiltrating%20lymphocytes%20and%20stromal%20tumor-infiltrating%20lymphocytes.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20categorized%20following%20previous%20studies%20as%20%26lt%3B1%25%20and%20%26gt%3B1%25.%20The%20cut-off%20for%20stromal%20tumor-infiltrating%20lymphocytes%20was%20chosen%20empirically%3A%20intermediate%20%26lt%3B60%25%20and%20high%20%26gt%3B60%25.%5CnRESULTS%3A%2086%20patients%20were%20included.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20not%20significantly%20associated%20with%20tumor%20metabolic%20metrics.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20not%20significantly%20associated%20with%20maximum%20standard%20uptake%20value%20%28p%3D0.16%29%2C%20or%20metabolic%20tumor%20volume%20%28p%3D0.19%29.%20Tumors%20with%20%26lt%3B1%25%20intraepithelial%20tumor-infiltrating%20lymphocytes%20score%20were%20associated%20with%20a%20higher%20MRI%20tumor%20size%20%28%5Cu2265%20median%29%20%2863.3%25%20vs%2039.3%25%2C%20p%3D0.04%29.%20Patients%20with%20pelvic%20lymph%20node%20uptake%20were%20significantly%20more%20frequent%20in%20patients%20with%20high%20stromal%20tumor-infiltrating%20lymphocytes%20score%20%28%5Cu226560%25%29%20%2861.5%25%20vs%2031.7%25%2C%20p%3D0.009%29.%5CnCONCLUSIONS%3A%20Poor%20or%20absent%20intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20associated%20with%20more%20advanced%20disease%20at%20diagnosis%20and%20larger%20tumor%20size.%20Tumor-infiltrating%20lymphocytes%20were%20not%20associated%20with%20tumor%20metabolic%20activity.%20Intraepithelial%20and%20stroma%20tumor-infiltrating%20lymphocytes%20are%20not%20redundant%20and%20should%20be%20assessed%20separately.%20Further%20work%20is%20needed%20to%20evaluate%20the%20association%20between%20tumor%20metabolic%20profile%20and%20immune%20populations%2C%20including%20different%20T-cell%20subtypes%20for%20patient%20selection%20for%20immunotherapy%20strategies.%22%2C%22date%22%3A%222024-04-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2023-004677%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222024-06-07T08%3A05%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22P3CRM7KI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ricotta%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRicotta%2C%20Giulio%2C%20Elodie%20Gauroy%2C%20Anne-Sophie%20Navarro%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BHow%20to%20Reduce%20Anterior%20Resection%20Syndrome%20and%20Post-Operative%20Complication%20after%20Rectosigmoid%20Resection.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2028%2C%202024%2C%20ijgc%26%23x2013%3B2024%26%23x2013%3B005306.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2024-005306%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2024-005306%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20to%20reduce%20anterior%20resection%20syndrome%20and%20post-operative%20complication%20after%20rectosigmoid%20resection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%22%2C%22lastName%22%3A%22Ricotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gauroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-03-28%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2024-005306%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222024-04-02T14%3A14%3A34Z%22%7D%7D%5D%7D
Del, Mathilde, Claire Illac, Mathilde Morisseau, Martina Aida Angeles, Anne Ducassou, Sarah Betrian, Guillaume Bataillon, et al. “Intraepithelial Tumor-Infiltrating Lymphocytes Shape Loco-Regional PET/CT Spread of Locally Advanced Cervical Cancer.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 34, no. 4 (April 1, 2024): 490–96. https://doi.org/10.1136/ijgc-2023-004677.
Ricotta, Giulio, Elodie Gauroy, Anne-Sophie Navarro, Alejandra Martinez, and Gwenael Ferron. “How to Reduce Anterior Resection Syndrome and Post-Operative Complication after Rectosigmoid Resection.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, March 28, 2024, ijgc–2024–005306. https://doi.org/10.1136/ijgc-2024-005306.
PUBLICATIONS 2023
7813506
FGRJFWV3
2023
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%228P27RTPE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Spagnolo%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSpagnolo%2C%20Emanuela%2C%20Alejandra%20Martinez%2C%20Andrea%20Mascar%26%23xF3%3Bs-Mart%26%23xED%3Bnez%2C%20Josep%20Mar%26%23xED%3B-Alexandre%2C%20Mar%26%23xED%3Ba%20Carbonell%2C%20Eva%20Gonz%26%23xE1%3Blez-Cant%26%23xF3%3B%2C%20Eva%20Manuela%20Pena-Burgos%2C%20et%20al.%20%26%23x201C%3BEvaluation%20of%20Immune%20Infiltrates%20in%20Ovarian%20Endometriosis%20and%20Endometriosis-Associated%20Ovarian%20Cancer%3A%20Relationship%20with%20Histological%20and%20Clinical%20Features.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Molecular%20Sciences%26lt%3B%5C%2Fi%26gt%3B%2024%2C%20no.%2015%20%28July%2028%2C%202023%29%3A%2012083.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms241512083%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms241512083%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20Immune%20Infiltrates%20in%20Ovarian%20Endometriosis%20and%20Endometriosis-Associated%20Ovarian%20Cancer%3A%20Relationship%20with%20Histological%20and%20Clinical%20Features%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Spagnolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Mascar%5Cu00f3s-Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josep%22%2C%22lastName%22%3A%22Mar%5Cu00ed-Alexandre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%22%2C%22lastName%22%3A%22Carbonell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Gonz%5Cu00e1lez-Cant%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20Manuela%22%2C%22lastName%22%3A%22Pena-Burgos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e1rbara%20Andrea%22%2C%22lastName%22%3A%22Mc%20Cormack%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarai%22%2C%22lastName%22%3A%22Tom%5Cu00e1s-P%5Cu00e9rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Gilabert-Estell%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Carrasco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%22%2C%22lastName%22%3A%22Hidalgo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22%5Cu00c1ngeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9s%22%2C%22lastName%22%3A%22Redondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandro%22%2C%22lastName%22%3A%22Gallego%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20the%20association%20between%20ovarian%20endometriosis%20%28OE%29%20and%20endometriosis-associated%20ovarian%20cancer%20%28EAOC%29%20is%20extensively%20documented%2C%20and%20misfunction%20of%20the%20immune%20system%20might%20be%20involved.%20The%20primary%20objective%20of%20this%20study%20was%20to%20identify%20and%20compare%20the%20spatial%20distribution%20of%20tumour-infiltrating%20lymphocytes%20%28TILs%29%20and%20tumour-associated%20macrophages%20%28TAMs%29%20in%20OE%20and%20EAOC.%20Secondary%20objectives%20included%20the%20analysis%20of%20the%20relationship%20between%20immunosuppressive%20populations%20and%20T-cell%20exhaustion%20markers%20in%20both%20groups.%5CnMETHODS%3A%20TILs%20%28CD3%2C%20CD4%2C%20and%20CD8%29%20and%20macrophages%20%28CD163%29%20were%20assessed%20by%20immunochemistry.%20Exhaustion%20markers%20%28PD-1%2C%20TIM3%2C%20CD39%2C%20and%20FOXP3%29%20and%20their%20relationship%20with%20tumour-associated%20macrophages%20%28CD163%29%20were%20assessed%20by%20immunofluorescence%20on%20paraffin-embedded%20samples%20from%20n%20%3D%2043%20OE%20and%20n%20%3D%2054%20EAOC%20patients.%5CnRESULTS%3A%20we%20observed%20a%20predominantly%20intraepithelial%20CD3%2B%20distribution%20in%20OE%20but%20both%20an%20intraepithelial%20and%20stromal%20pattern%20in%20EAOC%20%28p%20%26lt%3B%200.001%29.%20TILs%20were%20more%20abundant%20in%20OE%20%28p%20%26lt%3B%200.001%29%2C%20but%20higher%20TILs%20significantly%20correlated%20with%20a%20longer%20overall%20survival%20and%20disease-free%20survival%20in%20EAOC%20%28p%20%26lt%3B%200.05%29.%20CD39%20and%20FOXP3%20significantly%20correlated%20with%20each%20other%20and%20CD163%20%28p%20%26lt%3B%200.05%29%20at%20the%20epithelial%20level%20in%20moderate%5C%2Fintense%20CD4%20EAOC%2C%20whereas%20in%20moderate%5C%2Fintense%20CD8%2B%2C%20PD-1%2B%20and%20TIM3%2B%20significantly%20correlated%20%28p%20%3D%200.009%29.%20Finally%2C%20T-cell%20exhaustion%20markers%20FOXP3-CD39%20were%20decreased%20and%20PD-1-TIM3%20were%20significantly%20increased%20in%20EAOC%20%28p%20%26lt%3B%200.05%29.%5CnCONCLUSIONS%3A%20the%20dysregulation%20of%20TILs%2C%20TAMs%2C%20and%20T-cell%20exhaustion%20might%20play%20a%20role%20in%20the%20malignization%20of%20OE%20to%20EAOC.%22%2C%22date%22%3A%222023-07-28%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms241512083%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221422-0067%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222023-08-16T09%3A35%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22ATLKTGY4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Feliu%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFeliu%2C%20Virginie%2C%20Carlos%20Gomez-Roca%2C%20Marie%20Michelas%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Fran%26%23xE7%3Boise%20Lauz%26%23xE9%3Bral-Vizcaino%2C%20Anna%20Salvioni%2C%20Lise%20Scandella%2C%20et%20al.%20%26%23x201C%3BDistant%20Antimetastatic%20Effect%20of%20Enterotropic%20Colon%20Cancer-Derived%20%26%23x3B1%3B4%26%23x3B2%3B7%2BCD8%2B%20T%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScience%20Immunology%26lt%3B%5C%2Fi%26gt%3B%208%2C%20no.%2084%20%28June%202%2C%202023%29%3A%20eadg8841.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fsciimmunol.adg8841%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fsciimmunol.adg8841%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Distant%20antimetastatic%20effect%20of%20enterotropic%20colon%20cancer-derived%20%5Cu03b14%5Cu03b27%2BCD8%2B%20T%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Feliu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Lauz%5Cu00e9ral-Vizcaino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Salvioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Scandella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emeline%22%2C%22lastName%22%3A%22Sarot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20high%20prognostic%20value%20of%20immune%20infiltrates%20in%20colorectal%20cancer%20%28CRC%29%2C%20metastatic%20disease%20remains%20resistant%20to%20immunotherapy%20by%20immune%20checkpoint%20blockade%20%28ICB%29.%20Here%2C%20we%20show%2C%20in%20metastatic%20CRC%20preclinical%20models%2C%20that%20orthotopically%20implanted%20primary%20colon%20tumors%20exert%20a%20colon-specific%20antimetastatic%20effect%20on%20distant%20hepatic%20lesions.%20Enterotropic%20%5Cu03b14%5Cu03b27%20integrin-expressing%20neoantigen-specific%20CD8%20T%20cells%20were%20key%20components%20of%20the%20antimetastatic%20effect.%20Accordingly%2C%20the%20presence%20of%20concomitant%20colon%20tumors%20improved%20control%20of%20liver%20lesions%20by%20anti-PD-L1%20proof-of-concept%20immunotherapy%20and%20generated%20protective%20immune%20memory%2C%20whereas%20partial%20depletion%20of%20%5Cu03b14%5Cu03b27%2B%20cells%20abrogated%20control%20of%20metastases.%20Last%2C%20in%20patients%20with%20metastatic%20CRC%2C%20response%20to%20ICB%20was%20associated%20with%20expression%20of%20%5Cu03b14%5Cu03b27%20integrin%20in%20metastases%20and%20with%20circulating%20%5Cu03b14%5Cu03b27%2B%20CD8%20T%20cells.%20Our%20findings%20identify%20a%20systemic%20cancer%20immunosurveillance%20role%20for%20gut-primed%20tumor-specific%20%5Cu03b14%5Cu03b27%2B%20CD8%20T%20cells.%22%2C%22date%22%3A%222023-06-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1126%5C%2Fsciimmunol.adg8841%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222470-9468%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222023-06-09T12%3A24%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22P6GFFJPW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mart%5Cu00ednez%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMart%26%23xED%3Bnez%2C%20Alejandra%2C%20Cyrus%20Chargari%2C%20Elsa%20Kalbacher%2C%20Anne-Lise%20Gaillard%2C%20Alexandra%20Leary%2C%20Martin%20Koskas%2C%20Nicol%26%23xE1%3Bs%20Chopin%2C%20et%20al.%20%26%23x201C%3BRecommandations%20pour%20la%20pratique%20clinique%20Nice%5C%2FSaint-Paul-de-Vence%202022%26%23x2013%3B2023%26%23x202F%3B%3A%20prise%20en%20charge%20du%20cancer%20de%20l%26%23x2019%3Bendom%26%23xE8%3Btre%20localis%26%23xE9%3B.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20110%2C%20no.%206S%20%28June%202023%29%3A%206S20-26S33.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0007-4551%2823%2900331-4%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0007-4551%2823%2900331-4%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Recommandations%20pour%20la%20pratique%20clinique%20Nice%5C%2FSaint-Paul-de-Vence%202022%5Cu20132023%20%3A%20prise%20en%20charge%20du%20cancer%20de%20l%27endom%5Cu00e8tre%20localis%5Cu00e9.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Mart%5Cu00ednez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrus%22%2C%22lastName%22%3A%22Chargari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elsa%22%2C%22lastName%22%3A%22Kalbacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Lise%22%2C%22lastName%22%3A%22Gaillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Leary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Koskas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicol%5Cu00e1s%22%2C%22lastName%22%3A%22Chopin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Agathe%22%2C%22lastName%22%3A%22Serre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Claire%22%2C%22lastName%22%3A%22Hardy-Bessard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ch%5Cu00e9rif%22%2C%22lastName%22%3A%22Akladios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Lecuru%22%7D%5D%2C%22abstractNote%22%3A%22Recommendations%20for%20clinical%20practice%2C%20Nice%5C%2FSaint-Paul-de-Vence%202022-2023%3A%20Management%20of%20localized%20endometrial%20cancer%20Endometrial%20cancer%20is%20the%20most%20frequent%20gynecological%20cancers%20in%20industrialized%20countries%20and%20its%20incidence%20increases.%20The%20newmolecularclassification%20allows%20determination%20of%20the%20risk%20of%20recurrence%20and%20helps%20orienting%20therapeutic%20management.%20Surgery%20remains%20the%20cornerstone%20of%20treatment.%20Minimally%20invasive%20approach%20must%20be%20preferred%20for%20stages%20I%20and%20II.%20Surgery%20includes%20hysterectomy%20with%20bilateral%20adnexectomy%2C%20sentinel%20lymph%20node%20biopsy%20even%20in%20high%20risk%20diseases%20and%20omentectomy%20for%20non-endometrioid%20tumors%20%28except%20in%20case%20of%20clear%20cells%20tumors%29.%20Fertility%20preservation%20can%20be%20proposed%20in%20low%20grade%2C%20stage%20I%20tumors%20without%20myometrial%20involvement.%20In%20stage%20III%5C%2FIV%20disease%2C%20lymph%20node%20debulking%20without%20totallymphadenectomy%20is%20indicated.%20In%20case%20of%20peritoneal%20carcinomatosis%2C%20first-line%20cytoreductive%20surgery%20is%20recommended%20if%20complete%20resection%20can%20be%20achieved.%20Adjuvant%20therapy%20is%20not%20recommended%20in%20low%20risk%20tumors.%20In%20intermediate%20risk%20tumors%2C%20curietherapy%20is%20indicated.%20In%20tumors%20with%20high-intermediate%20risk%2C%20curietherapy%20and%20external%20radiotherapy%20are%20indicated%20according%20to%20prognostic%20factors%20%28stage%20II%2C%20lymphovascular%20invasion%29%3B%20adjuvant%20chemotherapy%20can%20be%20considered%20on%20a%20case-by-case%20basis.%20In%20high%20risk%20tumors%2C%20chemotherapy%20and%20external%20radiotherapy%20are%20recommended%20using%20a%20concomitant%20or%20sequential%20approach.%22%2C%22date%22%3A%222023-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS0007-4551%2823%2900331-4%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221769-6917%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222023-08-16T09%3A32%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22UP7QT2P5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Martinez%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMartinez%2C%20Alejandra%2C%20Fabrice%20Lecuru%2C%20Nicol%26%23xF2%3B%20Bizzarri%2C%20Cyrus%20Chargari%2C%20Anne%20Ducassou%2C%20Anna%20Fagotti%2C%20Francesco%20Fanfani%2C%20et%20al.%20%26%23x201C%3BPARa-aOrtic%20LymphAdenectomy%20in%20Locally%20Advanced%20Cervical%20Cancer%20%28PAROLA%20Trial%29%3A%20A%20GINECO%2C%20ENGOT%2C%20and%20GCIG%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2030%2C%202023%2C%20ijgc%26%23x2013%3B2022%26%23x2013%3B004223.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2022-004223%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2022-004223%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PARa-aOrtic%20LymphAdenectomy%20in%20locally%20advanced%20cervical%20cancer%20%28PAROLA%20trial%29%3A%20a%20GINECO%2C%20ENGOT%2C%20and%20GCIG%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Lecuru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicol%5Cu00f2%22%2C%22lastName%22%3A%22Bizzarri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrus%22%2C%22lastName%22%3A%22Chargari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Fagotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Fanfani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Scambia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cibula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berta%22%2C%22lastName%22%3A%22D%5Cu00edaz-Feijoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil%20Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mustafa%20Zelal%22%2C%22lastName%22%3A%22Muallem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christhardt%22%2C%22lastName%22%3A%22Kohler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Luyckx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Kridelka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnieszka%22%2C%22lastName%22%3A%22Rychlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20G.%22%2C%22lastName%22%3A%22Gerestein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viola%22%2C%22lastName%22%3A%22Heinzelmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20T.%22%2C%22lastName%22%3A%22Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Frumovitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Betrian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christina%22%2C%22lastName%22%3A%22Fotopoulou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22PAROLA%20Study%20group%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Positron%20emission%20tomography%5C%2Fcomputed%20tomography%20%28PET%5C%2FCT%29%20fails%20to%20detect%20approximately%2025%25%20of%20aortic%20lymph%20node%20metastasis%20in%20patients%20with%20PET%5C%2FCT%20stage%20IIIC1%20cervical%20cancer.%20Surgical%20staging%20could%20lead%20to%20treatment%20modification%20and%20to%20improved%20para-aortic%20and%20distant%20control.%5CnPRIMARY%20OBJECTIVES%3A%20To%20demonstrate%20if%20chemoradiation%20with%20tailored%20external%20beam%20radiation%20field%20based%20on%20surgical%20staging%20and%20pathologic%20examination%20of%20the%20para-aortic%20lymph%20node%20is%20associated%20with%20improved%203-year%20disease-free%20survival%20compared%20with%20patients%20staged%20with%20PET%5C%2FCT%20staging%20only.%5CnSTUDY%20HYPOTHESIS%3A%20Surgical%20staging%20followed%20by%20tailored%20chemoradiation%20will%20improve%20disease-free%20survival%20while%20avoiding%20unnecessary%20prophylactic%20extended-field%20chemoradiation%20in%20patients%20with%20International%20Federation%20of%20Gynecology%20and%20Obstetrics%20%28FIGO%29%20stage%20IIIC1%20cervical%20cancer.%5CnTRIAL%20DESIGN%3A%20This%20is%20an%20international%20multicenter%2C%20randomized%2C%20phase%20III%20study.%20Eligible%20patients%20will%20be%20randomized%201%3A1%20between%20PET%5C%2FCT%20staging%20followed%20by%20chemoradiation%20%28control%20arm%29%2C%20or%20surgical%20staging%20followed%20by%20tailored%20chemo-radiation%20%28experimental%20arm%29.%20Randomization%20will%20be%20stratified%20by%20tumor%20stage%20according%20to%20TNM%20classification%2C%20center%2C%20and%20adjuvant%20treatment.%5CnMAJOR%20INCLUSION%5C%2FEXCLUSION%20CRITERIA%3A%20Main%20inclusion%20criteria%20are%20histologically%20proven%20PET%5C%2FCT%20FIGO%20stage%20IIIC1%20cervical%20cancer.%20Main%20exclusion%20criteria%20include%20unequivocal%20positive%20common%20iliac%20or%20para-aortic%20lymph%20node%20at%20pre-therapeutic%20imaging%20PET%5C%2FCT.%5CnPRIMARY%20ENDPOINTS%3A%20The%20primary%20endpoint%20is%20disease-free%20survival%20defined%20as%20the%20time%20from%20randomization%20until%20first%20relapse%20%28local%2C%20regional%2C%20or%20distant%29%2C%20or%20death%20from%20any%20cause.%5CnSAMPLE%20SIZE%3A%20510%20eligible%20patients%20ESTIMATED%20DATES%20FOR%20COMPLETING%20ACCRUAL%20AND%20PRESENTING%20RESULTS%3A%20The%20estimated%20date%20for%20completing%20accrual%20will%20be%20Q2%202027.%20The%20estimated%20date%20for%20presenting%20results%20will%20be%20Q4%202030.%5CnTRIAL%20REGISTRATION%20NUMBER%3A%20NCT05581121.%22%2C%22date%22%3A%222023-01-30%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2022-004223%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222023-02-01T09%3A52%3A28Z%22%7D%7D%5D%7D
Spagnolo, Emanuela, Alejandra Martinez, Andrea Mascarós-Martínez, Josep Marí-Alexandre, María Carbonell, Eva González-Cantó, Eva Manuela Pena-Burgos, et al. “Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian Cancer: Relationship with Histological and Clinical Features.” International Journal of Molecular Sciences 24, no. 15 (July 28, 2023): 12083. https://doi.org/10.3390/ijms241512083.
Feliu, Virginie, Carlos Gomez-Roca, Marie Michelas, Noémie Thébault, Françoise Lauzéral-Vizcaino, Anna Salvioni, Lise Scandella, et al. “Distant Antimetastatic Effect of Enterotropic Colon Cancer-Derived α4β7+CD8+ T Cells.” Science Immunology 8, no. 84 (June 2, 2023): eadg8841. https://doi.org/10.1126/sciimmunol.adg8841.
Martínez, Alejandra, Cyrus Chargari, Elsa Kalbacher, Anne-Lise Gaillard, Alexandra Leary, Martin Koskas, Nicolás Chopin, et al. “Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : prise en charge du cancer de l’endomètre localisé.” Bulletin Du Cancer 110, no. 6S (June 2023): 6S20-26S33. https://doi.org/10.1016/S0007-4551(23)00331-4.
Martinez, Alejandra, Fabrice Lecuru, Nicolò Bizzarri, Cyrus Chargari, Anne Ducassou, Anna Fagotti, Francesco Fanfani, et al. “PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer (PAROLA Trial): A GINECO, ENGOT, and GCIG Study.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, January 30, 2023, ijgc–2022–004223. https://doi.org/10.1136/ijgc-2022-004223.
PUBLICATIONS 2022
7813506
FGRJFWV3
2022
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226QXZUPH7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Martinez%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-16%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMartinez%2C%20Alejandra%2C%20Berta%20D%26%23xED%3Baz-Feijoo%2C%20and%20Denis%20Querleu.%20%26%23x201C%3BPara-Aortic%20Lymphadenectomy%20in%20Cervical%20Cancer%20Deserves%20a%20New%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecologic%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20September%2016%2C%202022%2C%20ijgc%26%23x2013%3B2022%26%23x2013%3B003910.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2022-003910%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2022-003910%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Para-aortic%20lymphadenectomy%20in%20cervical%20cancer%20deserves%20a%20new%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berta%22%2C%22lastName%22%3A%22D%5Cu00edaz-Feijoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-09-16%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2022-003910%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fijgc.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fijgc-2022-003910%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221048-891X%2C%201525-1438%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-09-19T08%3A57%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22E99DSI56%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Martinez-Gomez%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMartinez-Gomez%2C%20Carlos%2C%20Marie%20Michelas%2C%20Clara-Maria%20Scarlata%2C%20Anna%20Salvioni%2C%20Carlos%20Gomez-Roca%2C%20Victor%20Sarradin%2C%20Fran%26%23xE7%3Boise%20Lauz%26%23xE9%3Bral-Vizcaino%2C%20et%20al.%20%26%23x201C%3BCirculating%20Exhausted%20PD-1%2BCD39%2B%20Helper%20CD4%20T%20Cells%20Are%20Tumor-Antigen-Specific%20and%20Predict%20Response%20to%20PD-1%5C%2FPD-L1%20Axis%20Blockade.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2014%2C%20no.%2015%20%28July%2028%2C%202022%29%3A%203679.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14153679%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14153679%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Circulating%20Exhausted%20PD-1%2BCD39%2B%20Helper%20CD4%20T%20Cells%20Are%20Tumor-Antigen-Specific%20and%20Predict%20Response%20to%20PD-1%5C%2FPD-L1%20Axis%20Blockade%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez-Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Salvioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Sarradin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Lauz%5Cu00e9ral-Vizcaino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22F%5Cu00e9liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Dupret-Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Sarini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%5D%2C%22abstractNote%22%3A%22Tumor-infiltrating%20exhausted%20PD-1hiCD39%2B%20tumor-antigen%20%28Ag%29-specific%20CD4%20T%20cells%20contribute%20to%20the%20response%20to%20immune%20checkpoint%20blockade%20%28ICB%29%2C%20but%20their%20circulating%20counterparts%2C%20which%20could%20represent%20accessible%20biomarkers%2C%20have%20not%20been%20assessed.%20Here%2C%20we%20analyzed%20circulating%20PD-1%2BCD39%2B%20CD4%20T%20cells%20and%20show%20that%20this%20population%20was%20present%20at%20higher%20proportions%20in%20cancer%20patients%20than%20in%20healthy%20individuals%20and%20was%20enriched%20in%20activated%20HLA-DR%2B%20and%20ICOS%2B%20and%20proliferating%20KI67%2B%20cells%2C%20indicative%20of%20their%20involvement%20in%20ongoing%20immune%20responses.%20Among%20memory%20CD4%20T%20cells%2C%20this%20population%20contained%20the%20lowest%20proportions%20of%20cells%20producing%20effector%20cytokines%2C%20suggesting%20they%20were%20exhausted.%20In%20patients%20with%20HPV-induced%20malignancies%2C%20the%20PD-1%2BCD39%2B%20population%20contained%20high%20proportions%20of%20HPV%20Ag-specific%20T%20cells.%20In%20patients%20treated%20by%20ICB%20for%20HPV-induced%20tumors%2C%20the%20proportion%20of%20circulating%20PD-1%2BCD39%2B%20CD4%20T%20cells%20was%20predictive%20of%20the%20clinical%20response.%20Our%20results%20identify%20CD39%20expression%20as%20a%20surrogate%20marker%20of%20circulating%20helper%20tumor-Ag-specific%20CD4%20T%20cells.%22%2C%22date%22%3A%222022-07-28%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14153679%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-08-22T09%3A42%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22BUCNKVTA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Martinez%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-23%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMartinez%2C%20Alejandra%2C%20Elodie%20Chantalat%2C%20Martina%20Aida%20Angeles%2C%20Gw%26%23xE9%3Bna%26%23xEB%3Bl%20Ferron%2C%20Anne%20Ducassou%2C%20Manon%20Daix%2C%20Justine%20Attal%2C%20Sarah%20B%26%23xE9%3Btrian%2C%20Am%26%23xE9%3Blie%20Lusque%2C%20and%20Erwan%20Gabiache.%20%26%23x201C%3BMetabolic%20Activity%20Determines%20Survival%20Depending%20on%20the%20Level%20of%20Lymph%20Node%20Involvement%20in%20Cervical%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2022%2C%20no.%201%20%28July%2023%2C%202022%29%3A%20810.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-022-09785-w%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-022-09785-w%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metabolic%20activity%20determines%20survival%20depending%20on%20the%20level%20of%20lymph%20node%20involvement%20in%20cervical%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Chantalat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Attal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22B%5Cu00e9trian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Gabiache%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20To%20assess%20the%20impact%20of%20PET%5C%2FCT%20functional%20parameters%20on%20survival%2C%20locoregional%2C%20and%20distant%20failure%20according%20to%20the%20most%20distant%20level%20of%20lymph%20node%20%5B18F%5DFDG%20uptake%20in%20patients%20with%20locally%20advanced%20cervical%20cancer%20%28LACC%29.%5CnMETHODS%3A%20Retrospective%20study%20including%20148%20patients%20with%20LACC%20treated%20with%20concurrent%20chemoradiotherapy%20after%20PET%5C%2FCT%20and%20para-aortic%20lymph%20node%20%28PALN%29%20surgical%20staging.%20Two%20senior%20nuclear%20medicine%20physicians%20reviewed%20all%20PET%5C%2FCT%20exams%20and%20retrieved%20tumor%20and%20lymph%20node%20metabolic%20parameters%3A%20SUVmax%2C%20MTV%2C%20TLG.%20Oncological%20outcomes%20according%20to%20metabolic%20parameters%20and%20level%20of%20lymph%20node%20spread%20on%20PET%5C%2FCT%20were%20assessed.%5CnRESULTS%3A%20In%20patients%20without%20lymph%20node%20uptake%20on%20PET%5C%2FCT%2C%20high%20MTV%20values%20of%20the%20cervical%20tumor%20were%20associated%20with%20DFS%20%28HR%5Cu2009%3D%5Cu20095.14%2095%25CI%5Cu2009%3D%5Cu2009%5B2.15-12.31%5D%29%2C%20OS%20%28HR%5Cu2009%3D%5Cu20096.10%2095%25CI%5Cu2009%3D%5Cu2009%5B1.89-19.70%5D%29%2C%20and%20time%20to%20distant%20%28HR%5Cu2009%3D%5Cu20094.73%2095%25CI%5Cu2009%3D%5Cu2009%5B1.55-14.44%5D%29%20and%20locoregional%20recurrence%20%28HR%5Cu2009%3D%5Cu20095.18%2095%25CI%5Cu2009%3D%5Cu2009%5B1.72-15.60%5D%29.%20In%20patients%20with%20pelvic%20lymph%20node%20%28PLN%29%20uptake%20but%20without%20PALN%20uptake%20on%20%5B18F%5DFDG-PET%5C%2FCT%2C%20high%20MTV%20values%20of%20the%20cervical%20tumor%20were%20associated%20with%20DFS%20%28HR%5Cu2009%3D%5Cu20093.17%2095%25CI%5Cu2009%3D%5Cu2009%5B1.02-9.83%5D%29%20and%20OS%20%28HR%5Cu2009%3D%5Cu20093.46%2095%25CI%5Cu2009%3D%5Cu2009%5B0.96-12.50%5D%29%2C%20and%20the%20number%20of%20PLN%20fixations%20was%20associated%20with%20DFS%20%28HR%5Cu2009%3D%5Cu20091.30%2095%25CI%5Cu2009%3D%5Cu2009%5B1.10-1.53%5D%29%2C%20OS%20%28HR%5Cu2009%3D%5Cu20091.35%2095%25CI%5Cu2009%3D%5Cu2009%5B1.11-1.64%5D%29%2C%20and%20time%20to%20distant%20%28HR%5Cu2009%3D%5Cu20091.35%2095%25CI%5Cu2009%3D%5Cu2009%5B1.08-1.67%5D%29%20and%20locoregional%20recurrence%20%28HR%5Cu2009%3D%5Cu20091.31%2095%25CI%5Cu2009%3D%5Cu2009%5B1.08-1.59%5D%29.%20There%20was%20no%20significant%20association%20between%20cervical%20tumor%20metabolic%20or%20lymph%20node%20metrics%20and%20survival%20outcome%20in%20patients%20with%20PALN%20uptake.%5CnCONCLUSIONS%3A%20Cervical%20MTV%20is%20more%20accurate%20than%20SUVmax%20to%20predict%20survival%20outcome%20in%20patients%20with%20locoregional%20disease%20confined%20to%20the%20pelvis%20and%20should%20be%20implemented%20in%20routine%20clinical%20practice.%20Prognostic%20value%20of%20metabolic%20metrics%20disappears%20with%20PALN%20uptake%2C%20which%20is%20associated%20with%20distant%20failure%20in%20nearly%20half%20of%20patients.%22%2C%22date%22%3A%222022-07-23%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-022-09785-w%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221471-2407%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-08-25T07%3A40%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22MXLCE4LK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20Alicia%20Hern%26%23xE1%3Bndez%2C%20Asunci%26%23xF3%3Bn%20P%26%23xE9%3Brez-Benavente%2C%20Bastien%20Cabarrou%2C%20Emanuela%20Spagnolo%2C%20Agnieszka%20Rychlik%2C%20Amel%20Daboussi%2C%20et%20al.%20%26%23x201C%3BThe%20Effect%20of%20Major%20Postoperative%20Complications%20on%20Recurrence%20and%20Long-Term%20Survival%20after%20Cytoreductive%20Surgery%20for%20Ovarian%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%20166%2C%20no.%201%20%28July%202022%29%3A%208%26%23x2013%3B17.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.05.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.05.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20major%20postoperative%20complications%20on%20recurrence%20and%20long-term%20survival%20after%20cytoreductive%20surgery%20for%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asunci%5Cu00f3n%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Benavente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Spagnolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnieszka%22%2C%22lastName%22%3A%22Rychlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amel%22%2C%22lastName%22%3A%22Daboussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22B%5Cu00e9trian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil-Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20assess%20the%20impact%20on%20survival%20of%20major%20postoperative%20complications%20and%20to%20identify%20the%20factors%20associated%20with%20these%20complications%20in%20patients%20with%20advanced%20ovarian%20cancer%20after%20cytoreductive%20surgery.%5CnMETHODS%3A%20We%20designed%20a%20retrospective%20multicenter%20study%20collecting%20data%20from%20patients%20with%20IIIC-IV%20FIGO%20Stage%20ovarian%20cancer%20who%20had%20undergone%20either%20primary%20debulking%20surgery%20%28PDS%29%2C%20early%20interval%20debulking%20surgery%20%28IDS%29%20after%203-4%20cycles%20of%20neoadjuvant%20chemotherapy%2C%20or%20delayed%20debulking%20surgery%20%28DDS%29%20after%206%20cycles%2C%20with%20minimal%20or%20no%20residual%20disease%2C%20from%20January%202008%20to%20December%202015.%20Univariable%20and%20multivariable%20analyses%20were%20conducted%20to%20identify%20factors%20associated%20with%20major%20surgical%20complications%20%28%5Cu2265Grade%203%29.%20We%20assessed%20disease-free%20survival%20%28DFS%29%20and%20overall%20survival%20%28OS%29%20rates%20according%20to%20the%20occurrence%20of%20major%20postoperative%20complications.%5CnRESULTS%3A%20549%20women%20were%20included.%20The%20overall%20rate%20of%20major%20surgical%20complications%20was%2022.4%25.%20Patients%20who%20underwent%20PDS%20had%20a%20higher%20rate%20of%20major%20complications%20%2828.6%25%29%20than%20patients%20who%20underwent%20either%20early%20IDS%20%2823.2%25%29%20or%20DDS%20%2814.0%25%29.%20Multivariable%20analysis%20revealed%20that%20extensive%20peritonectomy%20and%20surgical%20timing%20were%20associated%20with%20the%20occurrence%20of%20major%20complications.%20Median%20DFS%20and%20OS%20were%2016.9%20months%20%2895%25CI%20%3D%20%5B13.7-18.4%5D%29%20and%2048.0%20months%20%2895%25CI%20%3D%20%5B37.2-73.1%5D%29%20for%20the%20group%20of%20patients%20with%20major%20complications%2C%20and%2020.1%20months%20%2895%25CI%20%3D%20%5B18.6-22.4%5D%29%20and%2056.7%20months%20%2895%25CI%20%3D%20%5B51.2-70.4%5D%29%20for%20the%20group%20without%20major%20complications.%20Multivariable%20analysis%20revealed%20that%20major%20surgical%20complications%20were%20significantly%20associated%20with%20DFS%2C%20but%20not%20with%20OS.%5CnCONCLUSIONS%3A%20Patients%20who%20experienced%20major%20surgical%20complications%20had%20reduced%20DFS%2C%20compared%20with%20patients%20without%20major%20morbidity.%20Extensive%20peritonectomy%20and%20surgical%20timing%20were%20predictive%20factors%20of%20postoperative%20morbidity.%22%2C%22date%22%3A%222022-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ygyno.2022.05.002%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221095-6859%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-06-28T07%3A46%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22B9WBALIX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daix%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-21%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDaix%2C%20Manon%2C%20Carlos%20Martinez%20Gomez%2C%20Martina%20Aida%20Angeles%2C%20St%26%23xE9%3Bphanie%20Tock%2C%20Laurence%20Gladieff%2C%20Erwan%20Gabiache%2C%20Eliane%20Mery%2C%20Alejandra%20Martinez%2C%20David%20Cibula%2C%20and%20Gw%26%23xE9%3Bna%26%23xEB%3Bl%20Ferron.%20%26%23x201C%3BExtended%20Pelvic%20Resection%20for%20Gynecological%20Malignancies%3A%20A%20Review%20of%20out-of-the-Box%20Surgery.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2021%2C%202022%2C%20S0090-8258%2822%2900174-3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.03.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.03.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extended%20pelvic%20resection%20for%20gynecological%20malignancies%3A%20A%20review%20of%20out-of-the-box%20surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez%20Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Tock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Gabiache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cibula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22The%20term%20%26%23039%3Bout-of-the-box%20surgery%26%23039%3B%20in%20gynecologic%20oncology%20was%20recently%20coined%20to%20describe%20the%20resection%20of%20tumor%20growing%20out%20of%20the%20endopelvic%20cavity.%20In%20the%20specific%20case%20of%20pelvic%20sidewall%20involvement%2C%20a%20laterally%20extended%20pelvic%20resection%20may%20be%20required.%20As%20previously%20defined%20by%20H%5Cu00f6ckel%2C%20this%20resection%20requires%20the%20en%20bloc%20removal%20of%20structures%20including%20the%20pelvic%20sidewall%20muscles%2C%20bones%2C%20nerves%2C%20and%5C%2For%20major%20vessels.%20This%20complex%20radical%20procedure%20leads%20to%20tumor-free%20margins%20in%20more%20than%2075%25%20of%20the%20patients%2C%20with%20reliable%20functional%20results.%20The%20rate%20of%20recurrence%20and%20overall%20survival%20are%20directly%20correlated%20with%20clear%20resection%20margins.%20Progress%20in%20imaging%2C%20surgical%20techniques%2C%20and%20perioperative%20care%20currently%20offer%20the%20opportunity%20to%20attempt%20surgical%20curative%20resection%20in%20selected%20patients%20for%20whom%20palliative%20therapy%20was%20the%20only%20alternative.%20However%2C%20the%20procedure%20is%20associated%20with%20a%20high%20rate%20of%20major%20postoperative%20complications%20affecting%20up%20to%2060%25%20of%20patients.%20Multidisciplinary%20expert%20centers%20are%20the%20most%20likely%20to%20achieve%20this%20complex%20surgery%20with%20favorable%20oncological%20outcomes.%20The%20aim%20of%20this%20review%20is%20to%20summarize%20the%20key%20issues%20of%20out-of-the-box%20surgery%20in%20gynecologic%20cancer.%22%2C%22date%22%3A%222022-03-21%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ygyno.2022.03.002%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221095-6859%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22RAE2P5XW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daix%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDaix%2C%20Manon%2C%20Martina%20Aida%20Angeles%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Leray%2C%20Kelig%20Vergriete%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BAnterior%20Pelvic%20Exenteration%20and%20Laterally%20Extended%20Pelvic%20Resection%3A%20A%20Step%20by%20Step%20Procedure.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%201%20%28January%202022%29%3A%20107%26%23x2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-003047%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-003047%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anterior%20pelvic%20exenteration%20and%20laterally%20extended%20pelvic%20resection%3A%20a%20step%20by%20step%20procedure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelig%22%2C%22lastName%22%3A%22Vergriete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2021-003047%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%223U3NWA3K%22%2C%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A32Z%22%7D%7D%5D%7D
Martinez, Alejandra, Berta Díaz-Feijoo, and Denis Querleu. “Para-Aortic Lymphadenectomy in Cervical Cancer Deserves a New Trial.” International Journal of Gynecologic Cancer, September 16, 2022, ijgc–2022–003910. https://doi.org/10.1136/ijgc-2022-003910.
Martinez-Gomez, Carlos, Marie Michelas, Clara-Maria Scarlata, Anna Salvioni, Carlos Gomez-Roca, Victor Sarradin, Françoise Lauzéral-Vizcaino, et al. “Circulating Exhausted PD-1+CD39+ Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade.” Cancers 14, no. 15 (July 28, 2022): 3679. https://doi.org/10.3390/cancers14153679.
Martinez, Alejandra, Elodie Chantalat, Martina Aida Angeles, Gwénaël Ferron, Anne Ducassou, Manon Daix, Justine Attal, Sarah Bétrian, Amélie Lusque, and Erwan Gabiache. “Metabolic Activity Determines Survival Depending on the Level of Lymph Node Involvement in Cervical Cancer.” BMC Cancer 22, no. 1 (July 23, 2022): 810. https://doi.org/10.1186/s12885-022-09785-w.
Angeles, Martina Aida, Alicia Hernández, Asunción Pérez-Benavente, Bastien Cabarrou, Emanuela Spagnolo, Agnieszka Rychlik, Amel Daboussi, et al. “The Effect of Major Postoperative Complications on Recurrence and Long-Term Survival after Cytoreductive Surgery for Ovarian Cancer.” Gynecologic Oncology 166, no. 1 (July 2022): 8–17. https://doi.org/10.1016/j.ygyno.2022.05.002.
Daix, Manon, Carlos Martinez Gomez, Martina Aida Angeles, Stéphanie Tock, Laurence Gladieff, Erwan Gabiache, Eliane Mery, Alejandra Martinez, David Cibula, and Gwénaël Ferron. “Extended Pelvic Resection for Gynecological Malignancies: A Review of out-of-the-Box Surgery.” Gynecologic Oncology, March 21, 2022, S0090-8258(22)00174-3. https://doi.org/10.1016/j.ygyno.2022.03.002.
Daix, Manon, Martina Aida Angeles, Hélène Leray, Kelig Vergriete, Alejandra Martinez, and Gwenael Ferron. “Anterior Pelvic Exenteration and Laterally Extended Pelvic Resection: A Step by Step Procedure.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 32, no. 1 (January 2022): 107–8. https://doi.org/10.1136/ijgc-2021-003047.
PUBLICATIONS 2021
7813506
FGRJFWV3
2021
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2244MCBTVI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Leray%2C%20Federico%20Migliorelli%2C%20Manon%20Daix%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BSurgical%20Approach%20of%20the%20Left%20Upper%20Quadrant%20for%20Ovarian%20Cancer%20in%2010%20Steps.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2031%2C%20no.%2011%20%28November%202021%29%3A%201488%26%23x2013%3B89.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-002963%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-002963%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Surgical%20approach%20of%20the%20left%20upper%20quadrant%20for%20ovarian%20cancer%20in%2010%20steps%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2021-002963%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22UV5Q4HZY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cerapio%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCerapio%2C%20Juan-Pablo%2C%20Marion%20Perrier%2C%20Camille-Charlotte%20Balan%26%23xE7%3Ba%2C%20Pauline%20Gravelle%2C%20Fr%26%23xE9%3Bderic%20Pont%2C%20Christel%20Devaud%2C%20Don-Marc%20Franchini%2C%20et%20al.%20%26%23x201C%3BPhased%20Differentiation%20of%20%26%23x393%3B%26%23x3B4%3B%20T%20and%20T%20CD8%20Tumor-Infiltrating%20Lymphocytes%20Revealed%20by%20Single-Cell%20Transcriptomics%20of%20Human%20Cancers.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncoimmunology%26lt%3B%5C%2Fi%26gt%3B%2010%2C%20no.%201%20%282021%29%3A%201939518.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2021.1939518%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2021.1939518%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phased%20differentiation%20of%20%5Cu03b3%5Cu03b4%20T%20and%20T%20CD8%20tumor-infiltrating%20lymphocytes%20revealed%20by%20single-cell%20transcriptomics%20of%20human%20cancers%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan-Pablo%22%2C%22lastName%22%3A%22Cerapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gravelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22F%5Cu00e9liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Quillet-Mary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ysebaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fournie%22%7D%5D%2C%22abstractNote%22%3A%22%5Cu03b3%5Cu03b4%20T%20lymphocytes%20diverge%20from%20conventional%20T%20CD8%20lymphocytes%20for%20ontogeny%2C%20homing%2C%20and%20antigen%20specificity%2C%20but%20whether%20their%20differentiation%20in%20tumors%20also%20deviates%20was%20unknown.%20Using%20innovative%20analyses%20of%20our%20original%20and%20~150%20published%20single-cell%20RNA%20sequencing%20datasets%20validated%20by%20phenotyping%20of%20human%20tumors%20and%20murine%20models%2C%20here%20we%20present%20the%20first%20high-resolution%20view%20of%20human%20%5Cu03b3%5Cu03b4%20T%20cell%20differentiation%20in%20cancer.%20While%20%5Cu03b3%5Cu03b4%20T%20lymphocytes%20prominently%20encompass%20TCRV%5Cu03b39%20cells%20more%20differentiated%20than%20T%20CD8%20in%20healthy%20donor%26%23039%3Bs%20blood%2C%20a%20different%20scenario%20is%20unveiled%20in%20tumors.%20Solid%20tumors%20and%20lymphomas%20are%20infiltrated%20by%20a%20majority%20of%20TCRV%5Cu03b3non9%20%5Cu03b3%5Cu03b4%20T%20cells%20which%20are%20quantitatively%20correlated%20and%20remarkably%20aligned%20with%20T%20CD8%20for%20differentiation%2C%20exhaustion%2C%20gene%20expression%20profile%2C%20and%20response%20to%20immune%20checkpoint%20therapy.%20This%20cancer-wide%20association%20is%20critical%20for%20developing%20cancer%20immunotherapies.%22%2C%22date%22%3A%222021%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F2162402X.2021.1939518%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222162-402X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-11-22T16%3A29%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22W6US9RSD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khalifa%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKhalifa%2C%20Jonathan%2C%20Julien%20Mazieres%2C%20Carlos%20Gomez-Roca%2C%20Maha%20Ayyoub%2C%20and%20Elizabeth%20Cohen-Jonathan%20Moyal.%20%26%23x201C%3BRadiotherapy%20in%20the%20Era%20of%20Immunotherapy%26%23xA0%3BWith%20a%20Focus%20on%20Non-Small-Cell%20Lung%20Cancer%3A%20Time%20to%20Revisit%20Ancient%20Dogmas%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2011%20%282021%29%3A%20662236.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2021.662236%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2021.662236%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiotherapy%20in%20the%20Era%20of%20Immunotherapy%5Cu00a0With%20a%20Focus%20on%20Non-Small-Cell%20Lung%20Cancer%3A%20Time%20to%20Revisit%20Ancient%20Dogmas%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Mazieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Cohen-Jonathan%22%2C%22lastName%22%3A%22Moyal%22%7D%5D%2C%22abstractNote%22%3A%22Radiation-induced%20immune%20effects%20have%20been%20extensively%20deciphered%20over%20the%20last%20few%20years%2C%20leading%20to%20the%20concept%20of%20the%20dual%20immune%20effect%20of%20radiotherapy%20with%20both%20immunostimulatory%20and%20immunosuppressive%20effects.%20This%20explains%20why%20radiotherapy%20alone%20is%20not%20able%20to%20drive%20a%20strong%20anti-tumor%20immune%20response%20in%20most%20cases%2C%20hence%20underlining%20the%20rationale%20for%20combining%20both%20radiotherapy%20and%20immunotherapy.%20This%20association%20has%20generated%20considerable%20interest%20and%20hundreds%20of%20trials%20are%20currently%20ongoing%20to%20assess%20such%20an%20association%20in%20oncology.%20However%2C%20while%20some%20trials%20have%20provided%20unprecedented%20results%20or%20shown%20much%20promise%2C%20many%20hopes%20have%20been%20dashed.%20Questions%20remain%2C%20therefore%2C%20as%20to%20how%20to%20optimize%20the%20combination%20of%20these%20treatment%20modalities.%20This%20narrative%20review%20aims%20at%20revisiting%20the%20old%2C%20well-established%20concepts%20of%20radiotherapy%20relating%20to%20dose%2C%20fractionation%2C%20target%20volumes%20and%20organs%20at%20risk%20in%20the%20era%20of%20immunotherapy.%20We%20then%20propose%20potential%20innovative%20approaches%20to%20be%20further%20assessed%20when%20considering%20a%20radio-immunotherapy%20association%2C%20especially%20in%20the%20field%20of%20non-small-cell%20lung%20cancer%20%28NSCLC%29.%20We%20finally%20propose%20a%20framework%20to%20optimize%20the%20association%2C%20with%20pragmatic%20approaches%20depending%20on%20the%20stage%20of%20the%20disease.%22%2C%22date%22%3A%222021%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffonc.2021.662236%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222234-943X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22MCWU4QSQ%22%5D%2C%22dateModified%22%3A%222021-06-16T11%3A46%3A20Z%22%7D%7D%5D%7D
Angeles, Martina Aida, Hélène Leray, Federico Migliorelli, Manon Daix, Alejandra Martinez, and Gwenael Ferron. “Surgical Approach of the Left Upper Quadrant for Ovarian Cancer in 10 Steps.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 31, no. 11 (November 2021): 1488–89. https://doi.org/10.1136/ijgc-2021-002963.
Cerapio, Juan-Pablo, Marion Perrier, Camille-Charlotte Balança, Pauline Gravelle, Fréderic Pont, Christel Devaud, Don-Marc Franchini, et al. “Phased Differentiation of Γδ T and T CD8 Tumor-Infiltrating Lymphocytes Revealed by Single-Cell Transcriptomics of Human Cancers.” Oncoimmunology 10, no. 1 (2021): 1939518. https://doi.org/10.1080/2162402X.2021.1939518.
Khalifa, Jonathan, Julien Mazieres, Carlos Gomez-Roca, Maha Ayyoub, and Elizabeth Cohen-Jonathan Moyal. “Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?” Frontiers in Oncology 11 (2021): 662236. https://doi.org/10.3389/fonc.2021.662236.
PUBLICATIONS 2020
7813506
FGRJFWV3
2020
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22TZDYZ79F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balan%5Cu00e7a%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBalan%26%23xE7%3Ba%2C%20Camille-Charlotte%2C%20Anna%20Salvioni%2C%20Clara-Maria%20Scarlata%2C%20Marie%20Michelas%2C%20Carlos%20Martinez-Gomez%2C%20Carlos%20Gomez-Roca%2C%20Victor%20Sarradin%2C%20et%20al.%20%26%23x201C%3BPD-1%20Blockade%20Restores%20Helper%20Activity%20of%20Tumor-Infiltrating%20Exhausted%20PD-1hiCD39%2B%20CD4%20T%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJCI%20Insight%26lt%3B%5C%2Fi%26gt%3B%2C%20December%2017%2C%202020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2Fjci.insight.142513%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2Fjci.insight.142513%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PD-1%20blockade%20restores%20helper%20activity%20of%20tumor-infiltrating%20exhausted%20PD-1hiCD39%2B%20CD4%20T%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Salvioni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez-Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Sarradin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Dupret-Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-12-17%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1172%5C%2Fjci.insight.142513%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Finsight.jci.org%5C%2Farticles%5C%2Fview%5C%2F142513%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222379-3708%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22QS3I9WIA%22%2C%22WVCHCN8C%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22UEG3I9S7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20Thomas%20Filleron%2C%20Mathieu%20Virazels%2C%20Carine%20Dufau%2C%20Jean%20Milh%26%23xE8%3Bs%2C%20C%26%23xE9%3Bcile%20Pages%2C%20Pascale%20Olivier%2C%20et%20al.%20%26%23x201C%3BCombining%20Nivolumab%20and%20Ipilimumab%20with%20Infliximab%20or%20Certolizumab%20in%20Patients%20with%20Advanced%20Melanoma%3A%20First%20Results%20of%20a%20Phase%201b%20Clinical%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Cancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20December%203%2C%202020%2C%20clincanres.3449.2020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-3449%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-3449%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Combining%20nivolumab%20and%20ipilimumab%20with%20infliximab%20or%20certolizumab%20in%20patients%20with%20advanced%20melanoma%3A%20first%20results%20of%20a%20phase%201b%20clinical%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Virazels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Milh%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Pages%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Brayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-12-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-20-3449%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fclincancerres.aacrjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1158%5C%2F1078-0432.CCR-20-3449%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221078-0432%2C%201557-3265%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22JKYPDFWE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Weulersse%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-13%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWeulersse%2C%20Marianne%2C%20Assia%20Asrir%2C%20Andrea%20C.%20Pichler%2C%20Lea%20Lemaitre%2C%20Matthias%20Braun%2C%20Nadege%20Carrie%2C%20Marie-Veronique%20Joubert%2C%20et%20al.%20%26%23x201C%3BEomes-Dependent%20Loss%20of%20the%20Co-Activating%20Receptor%20CD226%20Restrains%20CD8%28%2B%29%20T%20Cell%20Anti-Tumor%20Functions%20and%20Limits%20the%20Efficacy%20of%20Cancer%20Immunotherapy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BImmunity%26lt%3B%5C%2Fi%26gt%3B%2053%2C%20no.%204%20%28October%2013%2C%202020%29%3A%20824-839.e10.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.immuni.2020.09.006%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.immuni.2020.09.006%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Eomes-Dependent%20Loss%20of%20the%20Co-activating%20Receptor%20CD226%20Restrains%20CD8%28%2B%29%20T%20Cell%20Anti-tumor%20Functions%20and%20Limits%20the%20Efficacy%20of%20Cancer%20Immunotherapy.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marianne%22%2C%22lastName%22%3A%22Weulersse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Assia%22%2C%22lastName%22%3A%22Asrir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%20C.%22%2C%22lastName%22%3A%22Pichler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lea%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Braun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadege%22%2C%22lastName%22%3A%22Carrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Veronique%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Le%20Moine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Do%20Souto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Gaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Indrajit%22%2C%22lastName%22%3A%22Das%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Brauns%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara%20M.%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Morandi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashmitha%22%2C%22lastName%22%3A%22Sundarrajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Cuisinier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Buisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Maheo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahar%22%2C%22lastName%22%3A%22Kassem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arantxa%22%2C%22lastName%22%3A%22Agesta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Verhoeyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Mazieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Dupre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Gossye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Guillerey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20S.%22%2C%22lastName%22%3A%22Dejean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelhadi%22%2C%22lastName%22%3A%22Saoudi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Goriely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herve%22%2C%22lastName%22%3A%22Avet-Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Bald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20J.%22%2C%22lastName%22%3A%22Smyth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Martinet%22%7D%5D%2C%22abstractNote%22%3A%22CD8%28%2B%29%20T%20cells%20within%20the%20tumor%20microenvironment%20%28TME%29%20are%20exposed%20to%20various%20signals%20that%20ultimately%20determine%20functional%20outcomes.%20Here%2C%20we%20examined%20the%20role%20of%20the%20co-activating%20receptor%20CD226%20%28DNAM-1%29%20in%20CD8%28%2B%29%20T%20cell%20function.%20The%20absence%20of%20CD226%20expression%20identified%20a%20subset%20of%20dysfunctional%20CD8%28%2B%29%20T%20cells%20present%20in%20peripheral%20blood%20of%20healthy%20individuals.%20These%20cells%20exhibited%20reduced%20LFA-1%20activation%2C%20altered%20TCR%20signaling%2C%20and%20a%20distinct%20transcriptomic%20program%20upon%20stimulation.%20CD226%28neg%29%20CD8%28%2B%29%20T%20cells%20accumulated%20in%20human%20and%20mouse%20tumors%20of%20diverse%20origin%20through%20an%20antigen-specific%20mechanism%20involving%20the%20transcriptional%20regulator%20Eomesodermin%20%28Eomes%29.%20Despite%20similar%20expression%20of%20co-inhibitory%20receptors%2C%20CD8%28%2B%29%20tumor-infiltrating%20lymphocyte%20failed%20to%20respond%20to%20anti-PD-1%20in%20the%20absence%20of%20CD226.%20Immune%20checkpoint%20blockade%20efficacy%20was%20hampered%20in%20Cd226%28-%5C%2F-%29%20mice.%20Anti-CD137%20%284-1BB%29%20agonists%20also%20stimulated%20Eomes-dependent%20CD226%20loss%20that%20limited%20the%20anti-tumor%20efficacy%20of%20this%20treatment.%20Thus%2C%20CD226%20loss%20restrains%20CD8%28%2B%29%20T%20cell%20function%20and%20limits%20the%20efficacy%20of%20cancer%20immunotherapy.%22%2C%22date%22%3A%222020%20Oct%2013%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.immuni.2020.09.006%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221097-4180%201074-7613%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%223U3NWA3K%22%2C%226FNA338P%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-16T14%3A03%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22DPIIILDF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fluckiger%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFluckiger%2C%20Aur%26%23xE9%3Blie%2C%20Romain%20Daill%26%23xE8%3Bre%2C%20Mohamed%20Sassi%2C%20Barbara%20Susanne%20Sixt%2C%20Peng%20Liu%2C%20Friedemann%20Loos%2C%20Corentin%20Richard%2C%20et%20al.%20%26%23x201C%3BCross-Reactivity%20between%20Tumor%20MHC%20Class%20I-Restricted%20Antigens%20and%20an%20Enterococcal%20Bacteriophage.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScience%20%28New%20York%2C%20N.Y.%29%26lt%3B%5C%2Fi%26gt%3B%20369%2C%20no.%206506%20%28August%2021%2C%202020%29%3A%20936%26%23x2013%3B42.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscience.aax0701%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscience.aax0701%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cross-reactivity%20between%20tumor%20MHC%20class%20I-restricted%20antigens%20and%20an%20enterococcal%20bacteriophage%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Fluckiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Daill%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Sassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%20Susanne%22%2C%22lastName%22%3A%22Sixt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Friedemann%22%2C%22lastName%22%3A%22Loos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corentin%22%2C%22lastName%22%3A%22Richard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Rabu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryam%20Tidjani%22%2C%22lastName%22%3A%22Alou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Goubet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gladys%22%2C%22lastName%22%3A%22Ferrere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Derosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Connie%20P.%20M.%22%2C%22lastName%22%3A%22Duong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meriem%22%2C%22lastName%22%3A%22Messaoudene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9anne%22%2C%22lastName%22%3A%22Gagn%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22De%20Sordi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Debarbieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Belinda%22%2C%22lastName%22%3A%22Palermo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Facciolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Boidot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Wheeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivo%20Gomperts%22%2C%22lastName%22%3A%22Boneca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zsofia%22%2C%22lastName%22%3A%22Sztupinszki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krisztian%22%2C%22lastName%22%3A%22Papp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Istvan%22%2C%22lastName%22%3A%22Csabai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edoardo%22%2C%22lastName%22%3A%22Pasolli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Segata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Lopez-Otin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoltan%22%2C%22lastName%22%3A%22Szallasi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Andre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerio%22%2C%22lastName%22%3A%22Iebba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentin%22%2C%22lastName%22%3A%22Quiniou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Klatzmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Boukhalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saber%22%2C%22lastName%22%3A%22Khelaifia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Raoult%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Albiges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Escudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Eggermont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fathia%22%2C%22lastName%22%3A%22Mami-Chouaib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Nistico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Ghiringhelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Routy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Labarri%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Cattoir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guido%22%2C%22lastName%22%3A%22Kroemer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Zitvogel%22%7D%5D%2C%22abstractNote%22%3A%22Intestinal%20microbiota%20have%20been%20proposed%20to%20induce%20commensal-specific%20memory%20T%20cells%20that%20cross-react%20with%20tumor-associated%20antigens.%20We%20identified%20major%20histocompatibility%20complex%20%28MHC%29%20class%20I-binding%20epitopes%20in%20the%20tail%20length%20tape%20measure%20protein%20%28TMP%29%20of%20a%20prophage%20found%20in%20the%20genome%20of%20the%20bacteriophage%20Enterococcus%20hirae%20Mice%20bearing%20E.%20hirae%20harboring%20this%20prophage%20mounted%20a%20TMP-specific%20H-2Kb-restricted%20CD8%2B%20T%20lymphocyte%20response%20upon%20immunotherapy%20with%20cyclophosphamide%20or%20anti-PD-1%20antibodies.%20Administration%20of%20bacterial%20strains%20engineered%20to%20express%20the%20TMP%20epitope%20improved%20immunotherapy%20in%20mice.%20In%20renal%20and%20lung%20cancer%20patients%2C%20the%20presence%20of%20the%20enterococcal%20prophage%20in%20stools%20and%20expression%20of%20a%20TMP-cross-reactive%20antigen%20by%20tumors%20correlated%20with%20long-term%20benefit%20of%20PD-1%20blockade%20therapy.%20In%20melanoma%20patients%2C%20T%20cell%20clones%20recognizing%20naturally%20processed%20cancer%20antigens%20that%20are%20cross-reactive%20with%20microbial%20peptides%20were%20detected.%22%2C%22date%22%3A%22Aug%2021%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1126%5C%2Fscience.aax0701%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221095-9203%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A14Z%22%7D%7D%2C%7B%22key%22%3A%2274Y4L2MB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Trimaglio%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-12%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTrimaglio%2C%20Giulia%2C%20Anne-Fran%26%23xE7%3Boise%20Tilkin-Mariam%26%23xE9%3B%2C%20Virginie%20Feliu%2C%20Fran%26%23xE7%3Boise%20Lauz%26%23xE9%3Bral-Vizcaino%2C%20Marie%20Tosolini%2C%20Carine%20Valle%2C%20Maha%20Ayyoub%2C%20et%20al.%20%26%23x201C%3BColon-Specific%20Immune%20Microenvironment%20Regulates%20Cancer%20Progression%20versus%20Rejection.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncoimmunology%26lt%3B%5C%2Fi%26gt%3B%209%2C%20no.%201%20%28July%2012%2C%202020%29%3A%201790125.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2020.1790125%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2020.1790125%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Colon-specific%20immune%20microenvironment%20regulates%20cancer%20progression%20versus%20rejection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulia%22%2C%22lastName%22%3A%22Trimaglio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Tilkin-Mariam%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Feliu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Lauz%5Cu00e9ral-Vizcaino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Neyrolles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Vergnolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoann%22%2C%22lastName%22%3A%22Rombouts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%5D%2C%22abstractNote%22%3A%22Immunotherapies%20have%20achieved%20clinical%20benefit%20in%20many%20types%20of%20cancer%20but%20remain%20limited%20to%20a%20subset%20of%20patients%20in%20colorectal%20cancer%20%28CRC%29.%20Resistance%20to%20immunotherapy%20can%20be%20attributed%20in%20part%20to%20tissue-specific%20factors%20constraining%20antitumor%20immunity.%20Thus%2C%20a%20better%20understanding%20of%20how%20the%20colon%20microenvironment%20shapes%20the%20immune%20response%20to%20CRC%20is%20needed%20to%20identify%20mechanisms%20of%20resistance%20to%20immunotherapies%20and%20guide%20the%20development%20of%20novel%20therapeutics.%20In%20an%20orthotopic%20mouse%20model%20of%20MC38-CRC%2C%20tumor%20progression%20was%20monitored%20by%20bioluminescence%20imaging%20and%20the%20immune%20signatures%20were%20assessed%20at%20a%20transcriptional%20level%20using%20NanoString%20and%20at%20a%20cellular%20level%20by%20flow%20cytometry.%20Despite%20initial%20tumor%20growth%20in%20all%20mice%2C%20only%2025%25%20to%2035%25%20of%20mice%20developed%20a%20progressive%20lethal%20CRC%20while%20the%20remaining%20animals%20spontaneously%20rejected%20their%20solid%20tumor.%20No%20tumor%20rejection%20was%20observed%20in%20the%20absence%20of%20adaptive%20immunity%2C%20nor%20when%20MC38%20cells%20were%20injected%20in%20non-orthotopic%20locations%2C%20subcutaneously%20or%20into%20the%20liver.%20We%20observed%20that%20progressive%20CRC%20tumors%20exhibited%20a%20protumor%20immune%20response%2C%20characterized%20by%20a%20regulatory%20T-lymphocyte%20pattern%2C%20discernible%20shortly%20post-tumor%20implantation%2C%20as%20well%20as%20suppressive%20myeloid%20cells.%20In%20contrast%2C%20tumor-rejecting%20mice%20presented%20an%20early%20inflammatory%20response%20and%20an%20antitumor%20microenvironment%20enriched%20in%20CD8%2B%20T%20cells.%20Taken%20together%2C%20our%20data%20demonstrate%20the%20role%20of%20the%20colon%20microenvironment%20in%20regulating%20the%20balance%20between%20anti%20or%20protumor%20immune%20responses.%20While%20emphasizing%20the%20relevance%20of%20the%20CRC%20orthotopic%20model%2C%20they%20set%20the%20basis%20for%20exploring%20the%20impact%20of%20the%20identified%20signatures%20in%20colon%20cancer%20response%20to%20immunotherapy.%22%2C%22date%22%3A%222020-07-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F2162402X.2020.1790125%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222162-4011%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A50%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22JGVYC2VA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Martinez%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMartinez%2C%20Alejandra%2C%20Jean-Pierre%20Delord%2C%20Maha%20Ayyoub%2C%20and%20Christel%20Devaud.%20%26%23x201C%3BPreclinical%20and%20Clinical%20Immunotherapeutic%20Strategies%20in%20Epithelial%20Ovarian%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%207%20%28July%202%2C%202020%29%3A%201761.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12071761%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12071761%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preclinical%20and%20Clinical%20Immunotherapeutic%20Strategies%20in%20Epithelial%20Ovarian%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%5D%2C%22abstractNote%22%3A%22In%20the%20past%2020%20years%2C%20the%20immune%20system%20has%20increasingly%20been%20recognized%20as%20a%20major%20player%20in%20tumor%20cell%20control%2C%20leading%20to%20considerable%20advances%20in%20cancer%20treatment.%20While%20promising%20with%20regards%20to%20melanoma%2C%20renal%20cancer%20and%20non-small%20cell%20lung%20cancer%2C%20immunotherapy%20provides%2C%20for%20the%20time%20being%2C%20limited%20success%20in%20other%20cancers%2C%20including%20ovarian%20cancer%2C%20potentially%20due%20to%20insufficient%20immunogenicity%20or%20to%20a%20particularly%20immunosuppressive%20microenvironment.%20In%20this%20review%2C%20we%20provide%20a%20global%20description%20of%20the%20immune%20context%20of%20ovarian%20cancer%2C%20in%20particular%20epithelial%20ovarian%20cancer%20%28EOC%29.%20We%20describe%20the%20adaptive%20and%20innate%20components%20involved%20in%20the%20EOC%20immune%20response%2C%20including%20infiltrating%20tumor-specific%20T%20lymphocytes%2C%20B%20lymphocytes%2C%20and%20natural%20killer%20and%20myeloid%20cells.%20In%20addition%2C%20we%20highlight%20the%20rationale%20behind%20the%20use%20of%20EOC%20preclinical%20mouse%20models%20to%20assess%20resistance%20to%20immunotherapy%2C%20and%20we%20summarize%20the%20main%20preclinical%20studies%20that%20yielded%20anti-EOC%20immunotherapeutic%20strategies.%20Finally%2C%20we%20focus%20on%20major%20published%20or%20ongoing%20immunotherapy%20clinical%20trials%20concerning%20EOC.%22%2C%22date%22%3A%222020-07-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12071761%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F7%5C%2F1761%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22LJQSY8VX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balan%5Cu00e7a%20et%20al.%22%2C%22parsedDate%22%3A%222020-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBalan%26%23xE7%3Ba%2C%20Camille-Charlotte%2C%20Clara-Maria%20Scarlata%2C%20Marie%20Michelas%2C%20Christel%20Devaud%2C%20Victor%20Sarradin%2C%20Camille%20Franchet%2C%20Carlos%20Martinez%20Gomez%2C%20et%20al.%20%26%23x201C%3BDual%20Relief%20of%20T-Lymphocyte%20Proliferation%20and%20Effector%20Function%20Underlies%20Response%20to%20PD-1%20Blockade%20in%20Epithelial%20Malignancies.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Immunology%20Research%26lt%3B%5C%2Fi%26gt%3B%208%2C%20no.%207%20%28July%202020%29%3A%20869%26%23x2013%3B82.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-19-0855%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-19-0855%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dual%20Relief%20of%20T-lymphocyte%20Proliferation%20and%20Effector%20Function%20Underlies%20Response%20to%20PD-1%20Blockade%20in%20Epithelial%20Malignancies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille-Charlotte%22%2C%22lastName%22%3A%22Balan%5Cu00e7a%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Michelas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christel%22%2C%22lastName%22%3A%22Devaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Sarradin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez%20Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Gomez-Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Heaugwane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Lauz%5Cu00e9ral-Vizcaino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Mir-Mesnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22F%5Cu00e9liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Motton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Tanguy%20Le%20Gac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Dupret-Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Sarini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Vairel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Illac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried-Vergnon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%5D%2C%22abstractNote%22%3A%22Although%20understanding%20of%20T-cell%20exhaustion%20is%20widely%20based%20on%20mouse%20models%2C%20its%20analysis%20in%20patients%20with%20cancer%20could%20provide%20clues%20indicating%20tumor%20sensitivity%20to%20immune%20checkpoint%20blockade%20%28ICB%29.%20Data%20suggest%20a%20role%20for%20costimulatory%20pathways%2C%20particularly%20CD28%2C%20in%20exhausted%20T-cell%20responsiveness%20to%20PD-1%5C%2FPD-L1%20blockade.%20Here%2C%20we%20used%20single-cell%20transcriptomic%2C%20phenotypic%2C%20and%20functional%20approaches%20to%20dissect%20the%20relation%20between%20CD8%2B%20T-cell%20exhaustion%2C%20CD28%20costimulation%2C%20and%20tumor%20specificity%20in%20head%20and%20neck%2C%20cervical%2C%20and%20ovarian%20cancers.%20We%20found%20that%20memory%20tumor-specific%20CD8%2B%20T%20cells%2C%20but%20not%20bystander%20cells%2C%20sequentially%20express%20immune%20checkpoints%20once%20they%20infiltrate%20tumors%2C%20leading%2C%20in%20situ%2C%20to%20a%20functionally%20exhausted%20population.%20Exhausted%20T%20cells%20were%20nonetheless%20endowed%20with%20effector%20and%20tumor%20residency%20potential%20but%20exhibited%20loss%20of%20the%20costimulatory%20receptor%20CD28%20in%20comparison%20with%20their%20circulating%20memory%20counterparts.%20Accordingly%2C%20PD-1%20inhibition%20improved%20proliferation%20of%20circulating%20tumor-specific%20CD8%2B%20T%20cells%20and%20reversed%20functional%20exhaustion%20of%20specific%20T%20cells%20at%20tumor%20sites.%20In%20agreement%20with%20their%20tumor%20specificity%2C%20high%20infiltration%20of%20tumors%20by%20exhausted%20cells%20was%20predictive%20of%20response%20to%20therapy%20and%20survival%20in%20ICB-treated%20patients%20with%20head%20and%20neck%20cancer.%20Our%20results%20showed%20that%20PD-1%20blockade-mediated%20proliferation%5C%2Freinvigoration%20of%20circulating%20memory%20T%20cells%20and%20local%20reversion%20of%20exhaustion%20occur%20concurrently%20to%20control%20tumors.%22%2C%22date%22%3A%22Jul%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1158%5C%2F2326-6066.CIR-19-0855%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222326-6074%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22QS3I9WIA%22%2C%22WVCHCN8C%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22YK5T475M%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pont%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPont%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%2C%20Marie%20Tosolini%2C%20Qing%20Gao%2C%20Marion%20Perrier%2C%20Miguel%20Madrid-Menc%26%23xED%3Ba%2C%20Tse%26%23xA0%3BShun%20Huang%2C%20Pierre%20Neuvial%2C%20Maha%20Ayyoub%2C%20Kristopher%20Nazor%2C%20and%20Jean-Jacques%20Fourni%26%23xE9%3B.%20%26%23x201C%3BSingle-Cell%20Virtual%20Cytometer%20Allows%20User-Friendly%20and%20Versatile%20Analysis%20and%20Visualization%20of%20Multimodal%20Single%20Cell%20RNAseq%20Datasets.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNAR%20Genomics%20and%20Bioinformatics%26lt%3B%5C%2Fi%26gt%3B%202%2C%20no.%202%20%28June%201%2C%202020%29%3A%20lqaa025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnargab%5C%2Flqaa025%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fnargab%5C%2Flqaa025%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single-Cell%20Virtual%20Cytometer%20allows%20user-friendly%20and%20versatile%20analysis%20and%20visualization%20of%20multimodal%20single%20cell%20RNAseq%20datasets%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qing%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Madrid-Menc%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tse%5Cu00a0Shun%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Neuvial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristopher%22%2C%22lastName%22%3A%22Nazor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20The%20development%20of%20single-cell%20transcriptomic%20technologies%20yields%20large%20datasets%20comprising%20multimodal%20informations%2C%20such%20as%20transcriptomes%20and%20immunophenotypes.%20Despite%20the%20current%20explosion%20of%20methods%20for%20pre-processing%20and%20integrating%20multimodal%20single-cell%20data%2C%20there%20is%20currently%20no%20user-friendly%20software%20to%20display%20easily%20and%20simultaneously%20both%20immunophenotype%20and%20transcriptome-based%20UMAP%5C%2Ft-SNE%20plots%20from%20the%20pre-processed%20data.%20Here%2C%20we%20introduce%20Single-Cell%20Virtual%20Cytometer%2C%20an%20open-source%20software%20for%20flow%20cytometry-like%20visualization%20and%20exploration%20of%20pre-processed%20multi-omics%20single%20cell%20datasets.%20Using%20an%20original%20CITE-seq%20dataset%20of%20PBMC%20from%20an%20healthy%20donor%2C%20we%20illustrate%20its%20use%20for%20the%20integrated%20analysis%20of%20transcriptomes%20and%20epitopes%20of%20functional%20maturation%20in%20human%20peripheral%20T%20lymphocytes.%20So%20this%20free%20and%20open-source%20algorithm%20constitutes%20a%20unique%20resource%20for%20biologists%20seeking%20for%20a%20user-friendly%20analytic%20tool%20for%20multimodal%20single%20cell%20datasets.%22%2C%22date%22%3A%222020-06-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fnargab%5C%2Flqaa025%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Facademic.oup.com%5C%2Fnargab%5C%2Farticle%5C%2Fdoi%5C%2F10.1093%5C%2Fnargab%5C%2Flqaa025%5C%2F5822687%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222631-9268%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22QS3I9WIA%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22P226WC3R%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Prat%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPrat%2C%20M%26%23xE9%3Blissa%2C%20Augustin%20Le%20Naour%2C%20Kimberley%20Coulson%2C%20Fanny%20Lem%26%23xE9%3Be%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Leray%2C%20Godefroy%20Jacquemin%2C%20Mouna%20Chirine%20Rahabi%2C%20et%20al.%20%26%23x201C%3BCirculating%20CD14%20%26lt%3Bsup%26gt%3Bhigh%26lt%3B%5C%2Fsup%26gt%3B%20CD16%20%26lt%3Bsup%26gt%3Blow%26lt%3B%5C%2Fsup%26gt%3B%20Intermediate%20Blood%20Monocytes%20as%20a%20Biomarker%20of%20Ascites%20Immune%20Status%20and%20Ovarian%20Cancer%20Progression.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20for%20ImmunoTherapy%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%208%2C%20no.%201%20%282020%29%3A%20e000472.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2019-000472%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2019-000472%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Circulating%20CD14%20%3Csup%3Ehigh%3C%5C%2Fsup%3E%20CD16%20%3Csup%3Elow%3C%5C%2Fsup%3E%20intermediate%20blood%20monocytes%20as%20a%20biomarker%20of%20ascites%20immune%20status%20and%20ovarian%20cancer%20progression%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lissa%22%2C%22lastName%22%3A%22Prat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%22%2C%22lastName%22%3A%22Le%20Naour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberley%22%2C%22lastName%22%3A%22Coulson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Lem%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Godefroy%22%2C%22lastName%22%3A%22Jacquemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mouna%20Chirine%22%2C%22lastName%22%3A%22Rahabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Authier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Barret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Tabah-Fisch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Prost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Couderc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Coste%22%7D%5D%2C%22abstractNote%22%3A%22Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Besides%20the%20interest%20of%20an%20early%20detection%20of%20ovarian%20cancer%2C%20there%20is%20an%20urgent%20need%20for%20new%20predictive%20and%20prognostic%20biomarkers%20of%20tumor%20development%20and%20cancer%20treatment.%20In%20healthy%20patients%2C%20circulating%20blood%20monocytes%20are%20typically%20subdivided%20into%20classical%20%2885%25%29%2C%20intermediate%20%285%25%29%20and%20non-classical%20%2810%25%29%20populations.%20Although%20these%20circulating%20monocyte%20subsets%20have%20been%20suggested%20as%20biomarkers%20in%20several%20diseases%2C%20few%20studies%20have%20investigate%20their%20potential%20as%20a%20predictive%20signature%20for%20tumor%20immune%20status%2Ctumor%20growth%20and%20treatment%20adaptation.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20In%20this%20study%2C%20we%20used%20a%20homogeneous%20cohort%20of%2028%20chemotherapy-na%5Cu00efve%20patients%20with%20ovarian%20cancer%20to%20evaluate%20monocyte%20subsets%20as%20biomarkers%20of%20the%20ascites%20immunological%20status.%20We%20evaluated%20the%20correlations%20between%20circulating%20monocyte%20subsets%20and%20immune%20cells%20and%20tumor%20burden%20in%20peritoneal%20ascites.%20Moreover%2C%20to%20validate%20the%20use%20of%20circulating%20monocyte%20subsets%20tofollow%20tumor%20progression%20and%20treatment%20response%2C%20we%20characterized%20blood%20monocytes%20from%20ovarian%20cancer%20patients%20included%20in%20a%20phase%201%20clinical%20trial%20at%20baseline%20and%20following%20murlentamab%20treatment.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20We%20demonstrate%20here%20a%20robust%20expansion%20of%20the%20intermediate%20blood%20monocytes%20%28IBMs%29%20in%20ovarian%20cancer%20patients.%20We%20establish%20a%20significant%20positive%20correlation%20between%20IBM%20percentage%20and%20tumor%5Cu2013associate%20macrophages%20with%20a%20CCR2%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20high%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5C%2FCD163%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20high%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5C%2FCD206%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20high%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5C%2FCD86%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20low%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20profile.%20Moreover%2C%20IBM%20expansion%20is%20associated%20with%20a%20decreased%20effector%5C%2Fregulatory%20T-cell%20ratio%20in%20ascites%20and%20with%20the%20presence%20of%20soluble%20immunosuppressive%20mediators.%20We%20also%20establish%20that%20IBM%20proportion%20positively%20correlates%20with%20the%20peritoneum%20tumor%20burden.%20Finally%2C%20the%20study%20of%20IBMs%20in%20patients%20with%20ovarian%20cancer%20under%20immunotherapy%20during%20the%20phase%20clinical%20trial%20supports%20IBMs%20to%20follow%20the%20evolution%20of%20tumor%20development%20and%20the%20treatment%20adaptation.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20This%20study%2C%20which%20links%20IBM%20level%20with%20immunosuppression%20and%20tumor%20burden%20in%20peritoneum%2C%20identifies%20IBMs%20as%20apotential%20predictive%20signature%20of%20ascites%20immune%20status%20and%20as%20a%20biomarker%20ofovarian%20cancer%20development%20and%20treatment%20response.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Trial%20registration%20number%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20EudraCT%3A%202015-004252-22%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20NCT02978755%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.%22%2C%22date%22%3A%2206%5C%2F2020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fjitc-2019-000472%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjitc.bmj.com%5C%2Flookup%5C%2Fdoi%5C%2F10.1136%5C%2Fjitc-2019-000472%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222051-1426%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A22Z%22%7D%7D%5D%7D
Balança, Camille-Charlotte, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, et al. “PD-1 Blockade Restores Helper Activity of Tumor-Infiltrating Exhausted PD-1hiCD39+ CD4 T Cells.” JCI Insight, December 17, 2020. https://doi.org/10.1172/jci.insight.142513.
Montfort, Anne, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pages, Pascale Olivier, et al. “Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase 1b Clinical Trial.” Clinical Cancer Research, December 3, 2020, clincanres.3449.2020. https://doi.org/10.1158/1078-0432.CCR-20-3449.
Weulersse, Marianne, Assia Asrir, Andrea C. Pichler, Lea Lemaitre, Matthias Braun, Nadege Carrie, Marie-Veronique Joubert, et al. “Eomes-Dependent Loss of the Co-Activating Receptor CD226 Restrains CD8(+) T Cell Anti-Tumor Functions and Limits the Efficacy of Cancer Immunotherapy.” Immunity 53, no. 4 (October 13, 2020): 824-839.e10. https://doi.org/10.1016/j.immuni.2020.09.006.
Fluckiger, Aurélie, Romain Daillère, Mohamed Sassi, Barbara Susanne Sixt, Peng Liu, Friedemann Loos, Corentin Richard, et al. “Cross-Reactivity between Tumor MHC Class I-Restricted Antigens and an Enterococcal Bacteriophage.” Science (New York, N.Y.) 369, no. 6506 (August 21, 2020): 936–42. https://doi.org/10.1126/science.aax0701.
Trimaglio, Giulia, Anne-Françoise Tilkin-Mariamé, Virginie Feliu, Françoise Lauzéral-Vizcaino, Marie Tosolini, Carine Valle, Maha Ayyoub, et al. “Colon-Specific Immune Microenvironment Regulates Cancer Progression versus Rejection.” Oncoimmunology 9, no. 1 (July 12, 2020): 1790125. https://doi.org/10.1080/2162402X.2020.1790125.
Martinez, Alejandra, Jean-Pierre Delord, Maha Ayyoub, and Christel Devaud. “Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer.” Cancers 12, no. 7 (July 2, 2020): 1761. https://doi.org/10.3390/cancers12071761.
Balança, Camille-Charlotte, Clara-Maria Scarlata, Marie Michelas, Christel Devaud, Victor Sarradin, Camille Franchet, Carlos Martinez Gomez, et al. “Dual Relief of T-Lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies.” Cancer Immunology Research 8, no. 7 (July 2020): 869–82. https://doi.org/10.1158/2326-6066.CIR-19-0855.
Pont, Frédéric, Marie Tosolini, Qing Gao, Marion Perrier, Miguel Madrid-Mencía, Tse Shun Huang, Pierre Neuvial, Maha Ayyoub, Kristopher Nazor, and Jean-Jacques Fournié. “Single-Cell Virtual Cytometer Allows User-Friendly and Versatile Analysis and Visualization of Multimodal Single Cell RNAseq Datasets.” NAR Genomics and Bioinformatics 2, no. 2 (June 1, 2020): lqaa025. https://doi.org/10.1093/nargab/lqaa025.
Prat, Mélissa, Augustin Le Naour, Kimberley Coulson, Fanny Lemée, Hélène Leray, Godefroy Jacquemin, Mouna Chirine Rahabi, et al. “Circulating CD14 high CD16 low Intermediate Blood Monocytes as a Biomarker of Ascites Immune Status and Ovarian Cancer Progression.” Journal for ImmunoTherapy of Cancer 8, no. 1 (2020): e000472. https://doi.org/10.1136/jitc-2019-000472.
PUBLICATIONS 2019
7813506
FGRJFWV3
2019
1
chicago-fullnote-bibliography
50
date
desc
43971
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22N2Y6QVUW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20Carine%20Dufau%2C%20C%26%23xE9%3Bline%20Colacios%2C%20Nathalie%20Andrieu-Abadie%2C%20Thierry%20Levade%2C%20Thomas%20Filleron%2C%20Jean-Pierre%20Delord%2C%20Maha%20Ayyoub%2C%20Nicolas%20Meyer%2C%20and%20Bruno%20S%26%23xE9%3Bgui.%20%26%23x201C%3BAnti-TNF%2C%20a%20Magic%20Bullet%20in%20Cancer%20Immunotherapy%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20for%20Immunotherapy%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%207%2C%20no.%201%20%28November%2014%2C%202019%29%3A%20303.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40425-019-0802-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40425-019-0802-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-TNF%2C%20a%20magic%20bullet%20in%20cancer%20immunotherapy%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22Immune%20checkpoint%20blockers%20%28ICB%29%20have%20revolutionized%20cancer%20therapy.%20However%2C%20complete%20response%20is%20observed%20in%20a%20minority%20of%20patients%20and%20most%20patients%20develop%20immune-related%20adverse%20events%20%28irAEs%29.%20These%20include%20colitis%2C%20which%20can%20be%20treated%20with%20anti-tumor%20necrosis%20factor%20%28TNF%29%20antibodies%20such%20as%20Infliximab.%20In%20a%20recent%20issue%20of%20the%20Journal%20for%20ImmunoTherapy%20of%20Cancer%2C%20Badran%20et%20al.%20reported%20that%20co-administering%20Infliximab%20together%20with%20ICB%20to%20five%20cancer%20patients%20prevents%20colitis%20recurrence%2C%20with%20four%20of%20them%20exhibiting%20overall%20disease%20stability.%20The%20basis%20for%20this%20treatment%20strategy%20stemmed%20from%20our%20pre-clinical%20demonstration%20that%20TNF%20contributes%20to%20resistance%20to%20anti-PD-1%20therapy.%20In%20agreement%20with%20this%20concept%2C%20we%20have%20shown%20that%20TNF%20blockers%20improve%20the%20anti-tumor%20therapeutic%20activity%20of%20ICB%20in%20mice%20and%20based%20on%20these%20findings%20we%20are%20currently%20evaluating%20the%20combination%20in%20melanoma%20patients%20enrolled%20in%20the%20TICIMEL%20clinical%20trial.%20Herein%2C%20%28i%29%20we%20discuss%20the%20scientific%20rationale%20for%20combining%20anti-TNF%20and%20ICB%20in%20cancer%20patients%2C%20%28ii%29%20comment%20on%20the%20paper%20published%20by%20Badran%20et%20al.%20and%20%28iii%29%20provide%20the%20TICIMEL%20clinical%20trial%20design.%22%2C%22date%22%3A%22Nov%2014%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40425-019-0802-y%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222051-1426%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A45Z%22%7D%7D%2C%7B%22key%22%3A%229NBPDPBB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Franchini%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFranchini%2C%20Don-Marc%2C%20Olivia%20Lanvin%2C%20Marie%20Tosolini%2C%20Emilie%20Patras%20de%20Campaigno%2C%20Anne%20Cammas%2C%20Sarah%20P%26%23xE9%3Bricart%2C%20Clara-Maria%20Scarlata%2C%20et%20al.%20%26%23x201C%3BMicrotubule-Driven%20Stress%20Granule%20Dynamics%20Regulate%20Inhibitory%20Immune%20Checkpoint%20Expression%20in%20T%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCell%20Reports%26lt%3B%5C%2Fi%26gt%3B%2026%2C%20no.%201%20%28January%202%2C%202019%29%3A%2094-107.e7.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2018.12.014%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2018.12.014%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Microtubule-Driven%20Stress%20Granule%20Dynamics%20Regulate%20Inhibitory%20Immune%20Checkpoint%20Expression%20in%20T%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Don-Marc%22%2C%22lastName%22%3A%22Franchini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Lanvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Patras%20de%20Campaigno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Cammas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara-Maria%22%2C%22lastName%22%3A%22Scarlata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Lebras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ligat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Pont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20B.%22%2C%22lastName%22%3A%22Arimondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryse%22%2C%22lastName%22%3A%22Lapeyre-Mestre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefania%22%2C%22lastName%22%3A%22Millevoi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20the%20clinical%20success%20of%20blocking%20inhibitory%20immune%20checkpoint%20receptors%20such%20as%20programmed%20cell%20death-1%20%28PD-1%29%20in%20cancer%2C%20the%20mechanisms%20controlling%20the%20expression%20of%20these%20receptors%20have%20not%20been%20fully%20elucidated.%20Here%2C%20we%20identify%20a%20post-transcriptional%20mechanism%20regulating%20PD-1%20expression%20in%20T%5Cu00a0cells.%20Upon%20activation%2C%20the%20PDCD1%20mRNA%20and%20ribonucleoprotein%20complexes%20coalesce%20into%20stress%20granules%20that%20require%20microtubules%20and%20the%20kinesin%5Cu00a01%20molecular%20motor%20to%20proceed%20to%20translation.%20Hence%2C%20PD-1%20expression%20is%20highly%20sensitive%20to%20microtubule%20or%20stress%20granule%20inhibitors%20targeting%20this%20pathway.%20Evidence%20from%20healthy%20donors%20and%20cancer%20patients%20reveals%20a%20common%20regulation%20for%20the%20translation%20of%20CTLA4%2C%20LAG3%2C%20TIM3%2C%20TIGIT%2C%20and%20BTLA%20but%20not%20of%20the%20stimulatory%20co-receptors%20OX40%2C%20GITR%2C%20and%204-1BB%20mRNAs.%20In%20patients%2C%20disproportionality%20analysis%20of%20immune-related%20adverse%20events%20for%20currently%20used%20microtubule%20drugs%20unveils%20a%20significantly%20higher%20risk%20of%20autoimmunity.%20Our%20findings%20reveal%20a%20fundamental%20mechanism%20of%20immunoregulation%20with%20great%20importance%20in%20cancer%20immunotherapy.%22%2C%22date%22%3A%22Jan%2002%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.celrep.2018.12.014%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222211-1247%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22FGRJFWV3%22%2C%22QS3I9WIA%22%2C%22WVCHCN8C%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A22%3A55Z%22%7D%7D%5D%7D
Montfort, Anne, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, and Bruno Ségui. “Anti-TNF, a Magic Bullet in Cancer Immunotherapy?” Journal for Immunotherapy of Cancer 7, no. 1 (November 14, 2019): 303. https://doi.org/10.1186/s40425-019-0802-y.
Franchini, Don-Marc, Olivia Lanvin, Marie Tosolini, Emilie Patras de Campaigno, Anne Cammas, Sarah Péricart, Clara-Maria Scarlata, et al. “Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells.” Cell Reports 26, no. 1 (January 2, 2019): 94-107.e7. https://doi.org/10.1016/j.celrep.2018.12.014.
LES MEMBRES DE L’ÉQUIPE
Partnerships & Funding
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
Toulouse – FR
CRCT-Oncopole Follow 1,434 1,195
Compte officiel du Centre de Recherches en Cancérologie de Toulouse
Prize for the best communication at the French Association for Pancreatic Cancer Research (AFRCP) day for @BousquetVaysse team at @crctoncopole
➡️
Nous contacter
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?
